An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)_±

A Review of the Literature of High Dose Seasonal Influenza Vaccine for Adults 65 Years and Older







TO PROMOTE AND PROTECT THE HEALTH OF CANADIANS THROUGH LEADERSHIP, PARTNERSHIP, INNOVATION AND ACTION IN PUBLIC HEALTH.

-Public Health Agency of Canada

Également disponible en français sous le titre :

Examen de la littérature sur le vaccin contre la grippe saisonnière à forte dose chez les adultes de 65 ans et plus.

This publication can be made available in alternative formats upon request.

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2016

Publication date:

This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged. However, multiple copy reproduction of this publication in whole or in part for purposes of resale or redistribution requires the prior written permission from the Minister of Public Works and Government Services Canada, Ottawa, Ontario K1A 0S5 or copyright.droitdauteur@pwgsc.gc.ca.

Cat.: HP40-150/2016E-PDF ISBN: 978-0-660-04060-8

Pub.: 150180

PREAMBLE

The National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada (hereafter referred to as the Agency) with ongoing and timely medical, scientific, and public health advice relating to immunization. The Agency acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and is disseminating this document for information purposes. People administering the vaccine should also be aware relevant product contents of the monograph(s). Recommendations for use and other information set out herein may differ from that set out in the product monograph(s) of the Canadian manufacturer(s) of the vaccine(s). Manufacturer(s) have sought approval of the vaccine(s) and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. NACI members and liaison members conduct themselves within the context of the Agency's Policy on Conflict of Interest, including yearly declaration of potential conflict of interest.

TABLE OF CONTENTS

EX	ECUTIVE SUMMARY	3
I. I	INTRODUCTION	4
II. I	METHODS	4
III. I	RESULTS	6
	III.1 Epidemiology	6
	III.2 Efficacy and Effectiveness	7
	III.3 Serological criteria for assessment of influenza vaccines	7
	III.4 Immunogenicity	8
	III.5 Safety and adverse events	10
IV.I	EVIDENCE GAPS	12
	IV.1 Older Adults with Risk Factors	12
	IV.2 Types of Vaccines Compared	12
V. I	DISCUSSION/SUMMARY	12
VI.	CONCLUSIONS	13
VII.	UPDATE TO THE REVIEW OF THE LITERATURE	14
VIII	I. LIST OF ABBREVIATIONS	16
IX.I	REFERENCES	17
ΑP	PENDIX A: SEARCH STRATEGY AND RESULTS	21
ΑP	PENDIX B: FLOW DIAGRAM	25
	PENDIX C: LEVEL OF EVIDENCE BASED ON RESEARCH DESIGN AND QUALITY TERNAL VALIDITY) RATING OF EVIDENCE	26
	PENDIX D: SUMMARY OF EVIDENCE RELATED TO EFFICACY/EFFECTIVENESS (3H DOSE INFLUENZA VACCINES IN ADULTS 65 YEARS AND OLDER	_



2 | A REVIEW OF THE LITERATURE OF HIGH DOSE SEASONAL INFLUENZA VACCINE FOR ADULTS 65 YEARS AND OLDER

APPENDIX E: SUMMARY OF EVIDENCE RELATED TO IMMUNOGENICITY O	
SEASONAL INFLUENZA VACCINES IN ADULTS 65 YEARS AND OLDER	31
APPENDIX F: SUMMARY OF EVIDENCE RELATED TO SAFETY OF HIGH DO	SE
SEASONAL INFLUENZA VACCINES IN ADULTS 65 YEARS AND OLDER	50



EXECUTIVE SUMMARY

Adults 65 years of age and older are at higher risk of becoming seriously ill or dying if they become sick with influenza, and their immune response to influenza vaccines is lower than that of younger people. Several influenza vaccines have been developed in an attempt to induce higher antibody responses that may increase effectiveness in older adults, including Fluad®, which is an adjuvanted vaccine with the same amount of antigen (15µg haemagglutinin [HA] per virus strain) as the standard inactivated influenza vaccine, Intanza®, which is an intradermally administered vaccine (15µg HA/strain), and Fluzone® High Dose vaccine, which has four times the concentration of influenza virus antigen as the standard inactivated influenza vaccine. As noted in the Statement on Seasonal Influenza Vaccine for 2015-2016 (subsequent to the completion of the initial review of the literature), Sanofi Pasteur confirmed that Intanza® is no longer available on the Canadian market, however studies involving Intanza® are still summarized in this review as this announcement was not made until after the preparation of this report. Additionally, Fluzone® High Dose vaccine has since (Autumn 2015) received authorization for use in Canada.

In one large randomized controlled trial, people 65 years and older who received Fluzone® High Dose were 18-24% less likely to have laboratory-confirmed influenza than people who received Fluzone® (standard dose). Fluzone® High Dose vaccine has been shown to have significantly higher rates of antibody production (seroconversion, seroprotection, and post-vaccination geometric mean antibody titres) than Fluzone® (15µg HA/strain) and the intradermal inactivated influenza vaccine, Intanza® (15 µg HA/strain). The high dose vaccine and the intradermal vaccine did induce higher rates of reaction post-injection than the standard dose, but they were short-lived.

In conclusion, in people 65 years of age and older, the inactivated influenza vaccine containing higher doses of antigen (15 μ g HA/strain for intradermal vaccine and >15 μ g HA/strain for intramuscular vaccine) induced relatively higher serologic responses. Reduced influenza illness compared to the standard dose intramuscular inactivated vaccine was demonstrated in a few studies. A higher rate of post-injection local adverse events was noted with the higher dose product.

Note: An update to the literature review was conducted to find new studies indexed between June 27, 2014 and June 22, 2015. The additional literature included support to the original findings (see Section VII for more details).



I. INTRODUCTION

Background

The risk of becoming severely ill or dying when infected with influenza increases as adults age. During the influenza seasons from 2003-04 through 2010-11, excepting the pandemc of 2009, 55-65% of hospital separations in Canada and about 87% of deaths due to influenza occurred in citizens 65 years or older, although this age group only made up about 14% of the population¹. Although vaccination against influenza is the best strategy to prevent illness², studies show a reduced response to vaccines as people age³, with the presence of one or more chronic diseases a marker for reduced response^{4,5}. Immunosenescence is hypothesized to play a role in older adults' response to vaccines. Goodwin et al.³ estimate that, after adjusting for vaccine and host factors, rates of seroconversion and seroprotection in older adults were 50-75% lower than that of younger adults.

In a recent meta-analysis, Beyer et al. 6 estimate that vaccine effectiveness against laboratory-confirmed influenza was about 49% (Cl_{95%} 33, 62) in adults 65 years and older. This is lower than the effectiveness of 59% (Cl_{95%} 51, 67) for healthy adults 18-64 years old as estimated by Osterholm et al. 7 in their meta-analysis of the literature. There is growing pressure to improve influenza vaccine effectiveness, especially in older adults who are at higher risk of complications when they contract influenza.

There are influenza vaccines specifically formulated for older adults. Fluad®, which is available in Canada, is an adjuvanted vaccine that has 15µg haemagglutinin of each strain in the vaccine and is injected intramuscularly; Intanza®, which was previously available in Canada, has 15µg haemagglutinin of each strain and is injected intradermally. The 15µg formulation of Intanza® is considered high-dose compared to the 9µg formulation that was intended for adults aged 18 to 59 years of age. Both the 9µg and 15µg intradermal products are no longer available in Canada. Fluzone® High Dose, which is authorized for use in Canada as of Autumn 2015, contains 60µg of haemagglutinin per strain and is injected intramuscularly. Another vaccine referred to in this review is Flublok®. It is an intramuscular, recombinant influenza vaccine that uses insect cells in the replication process rather than chicken eggs and contains 45µg of haemagglutinin of each strain. It is authorized in the United States of America for adults 18 years of age and older, but is not authorized in Canada.

Purpose and Objectives

The purpose of this report is to review, to assess, and to synthesize the currently available literature to determine whether the burden of influenza-related disease is lower in people 65 years and older (or subgroups thereof) who receive high dose trivalent inactivated influenza vaccine compared with those who receive standard dose inactivated trivalent, adjuvanted inactivated trivalent, or quadrivalent inactivated influenza vaccines.

II. METHODS

This project includes information for adults 65 years and older, with no limit on their underlying health conditions. Publications with data from a wider range of age groups are included when subgroup data are available for some or all of the target age group (65 years and older). The review includes all high dose influenza vaccines, whether authorized or not, but with clear explication of whether they are authorized in Canada, experimental, or authorized in other



countries^a. The review excludes the 2009 H1N1pdm vaccine and experimental pandemic vaccines (e.g., H5N1 or H7N9).

The literature search was conducted in three databases: Medline, Embase, and EBM reviews-Cochrane Central Register of Controlled Trials. The search strategy was designed with the keywords and limits intended to capture all the articles in these databases that were relevant to the systematic review's disease, interventions, outcomes, population and time period of interest. The search strategy applied to each of the three databases on June 27, 2014 to capture records published since January 1, 2000 is detailed in Appendix A. Clinical trials registered on clinicaltrials.gov were also downloaded and matched, as possible, with existing publications. Two studies had data available but were not yet published, or published only as abstract. These data were included in the review.

The search yielded 8338 non-duplicate records (Appendix B). Two individuals screened the titles and abstracts for relevance. Records were excluded if it was clear from their title and abstract that their study population did not contain at least some proportion of adults aged 65 years and older, they were not influenza vaccine related, or if it was only about pandemic influenza vaccines and did not investigate seasonal influenza in any analyses. Finally, records were excluded if it was clear that their outcomes did not include any of: efficacy or effectiveness information (laboratory-confirmed influenza, clinic orphysician visit, hospitalization, influenza-related mortality), immunological data (seroconversion, seroprotection, or antibody titres), or safety (reactogenicity, local, systemic, or adverse reactions). Upon applying these criteria, 7779 records were excluded. The remaining records were retrieved for full-text review.

Each of the 559 articles retrieved for full-text review were screened again for relevance by two reviewers. Articles were only excluded if they were assessed as ineligible by both reviewers. If the first and second reviewers could not agree on the article's eligibility, the article was assessed by a third reviewer. Articles were designated as ineligible if they had greater than 10% of their study population either outside the age range or did not provide separate analysis for the age group of interest. Articles were also excluded if they did not present some data, whether through sub-group analyses or otherwise, that were about seasonal influenza vaccines, including data about vaccine efficacy or effectiveness, immunogenicity, or safety or reactogenicity. In addition, secondary research articles were excluded, as well as articles that analyzed data that were already included in the review via another article (unless it added information pertinent to the review). Lastly, studies were excluded if they contained insufficient information to assess its eligibility for the review or if it was a foreign language article that could not be reliably translated to and assessed in English. Based on these criteria 531 articles were excluded upon full-text review.

All remaining articles were assessed with regard to the level of evidence (see Appendix C, Table 1) and the quality of the study (see Appendix C, Table 2). Appendix D contains extracted information on efficacy and effectiveness, Appendix E on immunogenicity, and Appendix F on safety.

^a At the time of preparation of the initial report, Intanza® was authorized and available for use in Canada. As of the 2015-16 influenza season, Intanza® is no longer available in Canada, but studies using this vaccine as a high-dose comparator are still summarized in this review.



III. RESULTS

III.1 Epidemiology

Illnesses caused by influenza viruses occur throughout the year with widespread seasonal waves happening almost every year. The annual global attack rate of influenza is estimated at 5-10% in adults and 20-30% in children⁸. Although rates of influenza infection are higher in children, rates of serious morbidity and mortality are highest in children younger than 2 years of age, adults 65 years of age or older, and people with underlying medical conditions^{8, 9}.

Molinari et al.¹² estimated attack rates of 20% of American children under 5 years of age, 10% in children 5-17 years, 6.6% in adults 18 to 64 years, and 9% in adults 65 years and older. Using the Canadian national surveillance system for monitoring influenza, FluWatch, from the 2011-12 to 2013-14 influenza season, seniors accounted for 21-44% of all influenza detections per season. A larger proportion of seniors tested positive for influenza A(H3) subtype (range: 35-56% per season) compared to influenza A(H1) (8-12%) or influenza B (20-37%) in the past three seasons, however this is also attributed in part to the predominance of A(H3N2) during 2011-12 and 2012-13. The number of laboratory-confirmed outbreaks in long-term care facilities reported to FluWatch ranged from 180 in the predominantly A(H1N1) 2013-2014 season to 676 in the predominantly A(H3N2) 2012-2013 season¹³.

An estimated 175,000 emergency department visits per year are attributable to influenza-related illnesses in Canada^{11, 14} ¹. Between 1997 and 2004, rates of visits to healthcare practitioners and emergency rooms for pneumonia and influenza-related illnesses were higher for Canadian children younger than 5 years of age (107/1000) and adults 65 years and older (81/1000) than for people 5 to 64 years old (34/1000)¹⁵.

It is also estimated that an average of 12,200 influenza related hospital admissions occur annually in Canada^{1,11,14}. Rates of hospitalization due to influenza are highest in adults 65 years and older (18/1000), followed by rates of 8/1000 for children younger than 5 years and 1/1000 in people 5 to 64 years old¹⁵. Data reported to FluWatch from the PHAC/CIHR Influenza Research Network (PCIRN) Serious Outcomes Surveillance (SOS) network indicates that for the 2011-12 through 2013-14 influenza seasons, people 65 years and older accounted for 33-68% of people hospitalized and 34-58% of people admitted to ICU who had laboratory-confirmed influenza. Adults 65 years and older account for approximately 15% of the Canadian population⁶¹.

In Canada, as many as 4,000 deaths (range 300 to 6700 annually) may be caused, directly or indirectly, by influenza^{14, 16}. The highest mortality rates are in people 65 years and older (108.8/100,000) followed by people 50-64 years old (4.0/100,000) and people younger than 50 years (0.04/100,000)¹⁶. Even among older adults, the estimated risk of influenza-attributable death increases with age, from 23/100,000 Canadians 65-69 years old to 831/100,000 in people 90 years and older¹⁷. The estimated risk of death due to influenza is about 12 times higher in older adults with chronic lung disease than those without chronic lung disease and about 5 times higher for those with heart disease than those without heart disease¹⁷. Data reported to FluWatch from the SOS network indicates that for the 2011-12 through 2013-14 influenza seasons, of people who had laboratory-confirmed influenza, people 65 years and older accounted for 55-85% of those who died.

The <u>NACI annual statement on seasonal influenza vaccine</u> contains a full background on influenza and a description of vaccines available for use in Canada.



III.2 Efficacy and Effectiveness

Four studies comparing the relative efficacy of high dose vaccines were identified and described below.

The relative efficacy of Fluzone® High Dose ($60\mu g$ HA/strain) compared with Fluzone® ($15\mu g$ HA/strain) has been evaluated in two studies to date. The first study of 9158 ambulatory, medically-stable adults 65 years and older was conducted in 2009-2010 during the H1N1 pandemic²¹. The relative efficacy was 12.5% in favour of Fluzone® High Dose against laboratory-confirmed influenza, but with exceedingly wide confidence bounds ($Cl_{95\%}$ -140, 66); in this study 21 of the 22 symptomatic cases of influenza were caused by the A(H1N1)pdm09 strain, which was not in the seasonal vaccine.

The second study was conducted in 2011-2012 and 2012-2013 22 . In this study of almost 32,000 older adults, 18-24% fewer illnesses caused by influenza occurred in people who received Fluzone® High Dose compared with those who received Fluzone® (standard dose). The relative efficacy against laboratory-confirmed influenza of the high dose vaccine compared to the standard dose vaccine was 18% ($\text{Cl}_{95\%}$ 5,30) in participants who provided swabs when they had an acute respiratory illness, with 2.0% and 2.4%, respectively, diagnosed with influenza. The relative efficacy against laboratory-confirmed influenza was 24% ($\text{Cl}_{95\%}$ 10,36), with 1.4% and 1.9%, respectively, diagnosed with influenza, in those who provided swabs when they had an influenza-like illness (i.e., acute respiratory illness with systemic symptom(s)).

The relative efficacy of FluBlok® (~45 μ g HA/strain), compared with Fluzone® (15 μ g HA/strain) against culture-confirmed influenza was 25%(Cl_{95%} -448, 96) in adults 65 years and older and 50% (Cl_{95%} -76, 68) against culture- or serologic-confirmed influenza in this small (N=836) trial conducted in the USA²³. FluBlok® is not authorized for use in Canada; in the USA, it is only authorized for use in adults 18-49 years of age²⁴.

The relative effectiveness of Intanza® (15µg HA/strain) compared with Inflexal® V (15µg HA/strain), a virosome-adjuvanted subunit influenza vaccine, was 33% (Cl_{95%} 15, 48) against influenza-related hospitalization, for community-dwelling older adults in Spain²⁵. This large (N=164,021) retrospective cohort study limited analysis to hospital admissions with either laboratory-confirmed influenza or a main hospital discharge diagnosis of influenza in 2011-2012. Neither of these vaccines are currently available in Canada.

III.3 Serological criteria for assessment of influenza vaccines

A common measure of immunogenicity is to assess the level of serum antibodies produced in response to antigens included in the vaccine through a laboratory test called a hemagglutination inhibition (HI) assay. Seroconversion is measured as the proportion of participants with a minimum of a four-fold increase from pre- to post-immunization titres (≤1:10 to ≥1:40 or at least 4-fold rise in antibody titres). Seroprotection is a measure of the proportion of participants with a HI titre of ≥1:40 (or ≥1:32 in some studies) post-vaccination²⁶ and is generally accepted as being correlated with a 50% reduction in the risk of influenza²⁷. The geometric mean titre (GMT) is the geometric mean of the participants' (average of the logarithmic values of the titres) serum antibodies. The geometric mean fold rise (GMFR) is the ratio of the post-vaccination/pre-vaccination serum anti-haemagglutinin antibody titres.

When comparing two vaccines, there are two commonly used assessments: 1) the geometric mean titre ratio (GMTR), which uses the ratio of the post-vaccination GMT of people receiving each vaccine, and 2) the difference in the proportion of people who seroconvert in each group²⁷.



Non-inferiority of a new vaccine when comparing it to a licensed vaccine requires that: 1) the ratio of the post-vaccine GMT (GMT_1/GMT_0) has an upper-bound of 2-sided 95% confidence interval (CI) of <1.5 [or lower bound of >0.67], and 2) the difference in seroconversion rates (seroconversion₁ – seroconversion₀) has an upper bound of 2-sided 95% CI of <10 percentage points.

Table 1: Criteria for assessment of seasonal influenza vaccines for adults 60 years and older (not for assessment of live attenuated vaccines)

Committee	Seroconversion (or	Seroprotection (1:40	GMFR	Requirement
	significant increase)	HA)		
Committee for	>30% of participants	>60% of participants	>2.0	At least one of
Proprietary Medicinal				three
Products (Europe) ²⁶				measures
Center for Biologics	Lower bound of 2-sided	Lower bound of 2-	NA	Meets both
Evaluation & Research	95% CI ≥30%	sided 95% CI ≥60%		
(USA) ²⁷				

III.4 Immunogenicity

Immunogenicity refers to the ability of a vaccine to induce an immune response and is used to predict vaccine efficacy. As stated in the previous section, there are three common measures of immune response: seroprotection, seroconversion, and level of antibody titres as measured by geometric means.

High (>15 μg HA/strain) versus Standard Dose (15 μg HA/strain) Intramuscular Vaccines

60µg HA/strain Inactivated Intramuscular Vaccines

Four studies available at the time of this review compared the rates of seroconversion for study participants receiving vaccine containing 60µg (high dose) versus 15µg (standard dose) haemagglutinin (HA) per influenza strain. Rates of seroconversion were about 19% higher (ranging from 10-28%) for those receiving the higher dose vaccine - across all three strains in the vaccines and in all four studies²⁸⁻³². In the two studies that assessed significance, the rates of seroconversion were significantly higher for all three strains in the vaccine^{28, 29}. Similarly, rates of seroconversion were higher for those receiving the high compared to standard dose vaccines for participants 75 years and older and for a cohort of participants with underlying cardiopulmonary disease²⁸.

Five studies report higher rates of seroprotection for older adults vaccinated with the 60µg/strain product compared to those vaccinated with 15µg/strain vaccines^{21, 28-33}. Four of the five studies assessed significance in these, seroprotection was significantly higher in the groups receiving the high dose vaccine for all three strains in three of the studies ^{28, 33, 34}, but only against A(H1N1) in the fourth study²⁹. The relative lack of difference in response to the high dose vaccine in the fourth study may be attributable to the fact that 78% of participants were vaccinated against the same influenza strains within 6 months prior to the study.

Geometric mean titre ratios (GMTR) of participants' responses to the high versus the standard dose influenza vaccines were reported by several authors and were calculated for those that provided group-specific post-vaccination titres for each of the vaccines. Seroresponse to the B strains in the vaccines was about 1.5 times greater (1.3-1.7) to the high dose vaccines than the standard dose vaccines. The GMTR of the A strains was about 1.8 times higher for those



9 | A REVIEW OF THE LITERATURE OF HIGH DOSE SEASONAL INFLUENZA VACCINE FOR ADULTS 65 YEARS AND OLDER

receiving the high dose vaccines compared to the standard dose vaccines; ranging from 1.6-2.3, depending on the study^{21, 28-33}.

One unpublished study³⁵ followed older adults for two years following vaccination with either 15-or 60µg HA/strain. There were no differences between the small (N=50) groups in their geometric mean antibody titres two years after vaccination.

Authors of one study reported that older adults vaccinated with Fluzone® High Dose had higher rates of seroconversion and seroprotection and the ratio of post-vaccination geometric mean titres was significantly higher (1.3-1.4 to 1.0) for all three strains compared with those who received Intanza® (15µg HA per strain)³².

30µg HA/strain Inactivated Intramuscular Vaccines

Della Cioppa et al.^{36, 37} conducted a trial comparing the immune responses of a small number of older adults to a range of levels of H3N2 antigen (6- versus 12- and 15- versus 30µg HA), a range of amounts of adjuvant (0-100% of the amount used in the licensed vaccine, Fluad®), and intradermal compared with intramuscular administration. There were no significant differences in seroresponse between people who received 15µg versus 30µg HA of A(H3N2) antigen intramuscularly or people who received 6µg versus 12µg HA of A(H3N2) antigen intradermally.

A trial comparing nursing home resident who received a double dose (two injections of 15µg HA/strain licensed influenza vaccine in the same arm on the same day) were compared with residents who received the standard single dose³⁸. A significantly higher proportion of residents who received a double dose seroconverted and were seroprotected against the A(H3N2) strain 25 days after vaccination, and remained so 84 days afterwards. There were no differences between the groups 106 days after vaccination. Only results for the A(H3N2) strain were reported.

60µg HA/strain Subunit Intramuscular Vaccines

In 1988 Palache et al.³⁹ conducted a randomized controlled trial in which older adults living in nursing homes in the Netherlands received 10-, 20-, or 60µg HA/strain trivalent subunit influenza vaccine (Duphar BV). The rates of seroprotection were higher for those who received the 60µg HA/strain vaccine than the vaccines with lower doses. The geometric mean titre ratio did not change by dose for the A(H1N1) antigen. However, for people receiving the 60µg/strain vaccine, the GMTR was 1.6 for A(H3N2) and 2.1 for the B strain compared to those receiving the 10µg/strain vaccine.

Recombinant Haemagglutinin Intramuscular Vaccines

A randomized controlled trial comparing the recombinant influenza vaccine Flublok®, containing ~45µg HA/strain with Fluzone® containing 15µg/strain was conducted with community-dwelling people 65 years and older²³. The rates of seroconversion were significantly higher for both A strains of influenza for those receiving the higher dose vaccine. On the other hand, the rates of seroprotection were similar for the two vaccines. The B strain could not be compared since the strains were not the same in the two vaccines.

A randomized controlled trial compared the immunogenicity of several antigen levels of a recombinant influenza vaccine with Fluzone® containing 15µg/strain in participants 65 years and older⁴⁰. The rates of seroprotection and seroconversion were higher for those receiving the 45µg and 135µg HA/strain of the recombinant vaccine than those receiving Fluzone® for the A(H3N2) strain but rates were similar for the A(H1N1) and B strains. In comparison, participants



receiving the 15µg/strain of recombinant vaccine had similar responses to the A(H3N2) strain and lower responses to both the A(H1N1) and B strains than those receiving Fluzone®.

High (>9µg HA/strain) Intradermal Influenza Vaccines

15µg HA/strain Inactivated Intradermal versus Standard Dose Inactivated Intramuscular Vaccines

Seven randomized controlled trials have been conducted with older adults comparing the immune responses of 15µg HA/strain intradermal influenza vaccines with 15µg HA/strain intramuscular vaccines ⁴¹⁻⁴⁷. The rates of seroconversion, seroprotection, and the GMTR were generally higher for people who received the high dose intradermal vaccine than those receiving standard dose intramuscular vaccines. However, in only two of the studies, both with large sample sizes, were the differences statistically significant ^{42, 46}. Arnou et al. ⁴⁶ vaccinated older adults with the same vaccine annually for three years. Although rates of seroconversion and seroprotection were higher for those receiving the intradermal vaccine in the first year of the study, the rates were similar between the groups in the next two years when the sample size greatly diminished. Holland et al. ⁴² reported superior response to the intradermal vaccine compared with the standard dose intramuscular vaccine based on GMTR and significantly higher rates of serconversion for all three strains. The ratio of post-vaccination geometric mean titres for those vaccinated with the intradermal compared with intramuscular vaccines was about 1.3 times higher (range 1.0 to 1.8) across all studies.

15µg HA/strain Inactivated Intradermal versus 60µg HA/strain Inactivated Intramuscular Vaccine In the one study that compared seroresponses, a higher percentage of participants receiving the 60µg HA/strain intramuscular vaccine seroconverted and were seroprotected than those receiving the 15µg HA/strain intradermal vaccine³². The post-vaccination geometric mean titres for those receiving the 60µg HA/strain intramuscular vaccine were significantly higher than those receiving the 15µg HA/strain intradermal vaccine.

15µg HA/strain Inactivated Intradermal versus Adjuvanted Standard Dose Intramuscular Vaccines

Five randomized trials compared serological responses for older adults vaccinated with 15µg HA/strain intradermal influenza vaccines and 15µg HA/strain adjuvanted intramuscular vaccines vaccines 15µg HA/strain adjuvanted intramuscular vaccine produced significantly higher rates of immunological response than the intradermal vaccine while the participants in the other four studies had similar rates of seroconversion, seroprotection, and had similar GMFR. The post-vaccination ratio of geometric mean titres for those vaccinated with inactivated intramuscular influenza vaccine with an adjuvant was slightly higher than those vaccinated with an intradermal vaccine - about 1.1-1.2 (range 0.9 to 1.3).

III.5 Safety and adverse events

In adults 60 years and older, common local reactions to influenza vaccines without adjuvant that are injected intramuscularly include redness, swelling, pain, and induration. Local reactions common to vaccines injected intradermally include itchiness, soreness, redness, swelling, pain, and induration. These reactions last 2-3 days and rarely interfere with normal activities. Systemic reactions common to adults 60 years and older who receive influenza vaccines include headache, malaise, myalgia, fatigue, arthralgia, and fever.



High (>15µg HA/strain) versus Standard Dose (15µg HA/strain) Intramuscular Vaccines 60µg HA/strain Inactivated Intramuscular Influenza Vaccines

The 60µg HA/strain vaccines produce a significantly higher rate of systemic reactions than the 15µg HA/strain vaccines to which they were compared. One study reported a higher rate of systemic reaction without specifying the specific reaction³². Other studies reported significantly higher rates of malaise²⁸, myalgia^{28, 31}, and moderate/severe fever²⁸.

Rates of systemic reactions in the first 7 days after vaccination include (15µg versus $60\mu g$, respectively): myalgia (15-18% vs. 13-29%), malaise (13-14% vs. 16-18%), headache (14-17% vs. 11-17%), and fever (0.5-2.3% vs. 0.7-4.4%)^{28, 29, 31}. Rates of local reactions include: (15µg versus $60\mu g$, respectively): pain (14-24% vs. 36-53%), redness (5-28 v 9-29%), and swelling (3-18% v 6-24%)^{28, 29, 31}.

Serious adverse events were similar in frequency between the 15- and 60-µg HA/strain vaccines. In 25,440 older adults who received the 60µg HA/strain vaccines, 6 (2.36/10,000) vaccine-related serious adverse events were reported including cardiac chest pain²¹, oculorespiratory syndrome²⁹, cranial nerve VI palsy³³, hypovolemic shock³³, acute disseminated encephalomyelitis³³, and Crohn's disease exacerbation²⁸. These events were classified by the study investigators as being vaccine-related.

30µg HA/strain Inactivated Intramuscular Influenza Vaccines

In the two studies there were no reported differences in the rate of local or systemic reactions for people who received the 15- or 30- µg HA/strain vaccines. There were no reported serious adverse events related to the vaccine among the 80 people who received the 30µg HA/strain vaccines^{30, 37}.

Recombinant Haemagglutinin Vaccines

Recombinant subunit influenza vaccines elicited significantly higher rates of injection site pain⁴⁰ and immediate injection site redness²³ than standard dose inactivated influenza vaccines. No serious adverse events were reported in the 730 recipients.

High (>9µg HA/strain) Dose Intradermal Vaccines

15µg HA/strain Intradermal

The intradermal administration of influenza vaccines produces significantly higher rates of local reaction including redness, swelling, induration, and pruritus than either of the standard dose inactivated vaccines (i.e. those with and those without adjuvant)^{41-46, 49, 50}. Rates of systemic and local reactions (non-adjuvanted intramuscular versus intradermal, respectively) include: headache (11-18% vs. 4-17%), myalgia (6-19% vs. 6-23%), malaise (6-13% vs. 5-20%), fever (0-4% vs. 1-3%), and pain (6-21% vs. 4-30%), redness (4-15% vs. 26-76%), swelling (2-13% vs. 19-62%), induration (5-17% vs. 25-64%), and pruritus (2-9% vs. 20-29%)^{41-43, 46, 50}.

Four severe adverse events that may have been related to receipt of the intradermal vaccine were reported in 4815 older adults (8.31/10,000) including myopericarditis⁴⁶, facial neuralgia⁴⁶, brachial neuritis⁴², and pneumonia⁴⁹.

For an overview of contraindications and precautions for influenza vaccines in general, please see the NACI annual statement on seasonal influenza vaccines.



IV. EVIDENCE GAPS

IV.1 Older Adults with Risk Factors

The majority of studies reviewed for this report were conducted with ambulatory, community-dwelling older adults without immune suppressing diseases and who were not using immune suppressing medication. Also, the mean age of the participants is in the early 70s, when the immune response is expected to be better than for older adults. Studies need to be completed in older adults with immune suppressing conditions or using immune suppressing medications, people who are institutionalized, and adults who are 75 years of age and older to determine whether these vaccines are as effective in these cohorts as they are in the younger, healthier cohorts of seniors.

IV.2 Types of Vaccines Compared

There are no studies, at present, to compare the efficacy or effectiveness of 60µg HA/strain inactivated intramuscular influenza vaccine to 1) 15µg HA/strain inactivated intramuscular influenza vaccine containing an adjuvant, or 2) 15µg HA/strain inactivated intradermal vaccine. Since these vaccines are manufactured specifically for use in older adults, a head-to-head comparison would be informative for decision-makers. Only one study compared the immune responses of older adults vaccinated with 60µg HA/strain to those vaccinated with 15µg HA/strain intradermal vaccine and none have compared the immunogenicity of the 60µg HA/strain product to 15µg HA/strain intramuscular influenza vaccine containing an adjuvant.

There are also no studies that compare any of these vaccines with the quadrivalent influenza vaccines. Although a previous review found similar immune responses and safety profiles for inactivated quadrivalent compared with inactivated trivalent influenza vaccines in older adults, no studies have assessed the efficacy or effectiveness of the quadrivalent vaccines in seniors.

V. DISCUSSION/SUMMARY

In one large randomized controlled trial, people 65 years and older who received Fluzone® High Dose were 18-24% less likely to have laboratory-confirmed influenza than people who received Fluzone® (standard dose)³³. The high dose vaccine was shown to have significantly higher rates of seroconversion and seroprotection than its 15µg HA/strain standard dose counterpart. The post-vaccination geometric mean titres of people receiving the high dose vaccine was about 1.5-1.8 times higher than those receiving the standard dose vaccine, indicating higher relative antibody immune response 28 days after vaccination. The high dose vaccine does, however, induce higher rates of reaction post-injection but they were short-lived.

Intanza® (15µg HA/strain), which was produced for adults 60 years and older, was shown in one retrospective cohort study to reduce influenza-related hospitalization by 33% compared to the standard dose virosomal subunit trivalent influenza vaccine in community-dwelling adults 65 years and older²⁵. Compared with standard dose intramuscular influenza vaccines, the rates of seroconversion and seroprotection are slightly higher in those receiving Intanza®. The post-vaccination geometric mean titres of people receiving Intanza® is about 1.3 times higher than those receiving the standard dose intramuscular vaccine. In comparison, people vaccinated with Intanza® (15µg HA/strain) had lower serological responses than those vaccinated with Fluzone® High Dose, but similar to those receiving adjuvanted formulations of influenza vaccines. The intradermal vaccine induced higher rates of reactogenicity than the non-adjuvanted intramuscular influenza vaccines.



VI. CONCLUSIONS

Higher dose intramuscular, trivalent inactivated influenza vaccine for older adults^b should provide superior protection compared with the standard dose intramuscular vaccines, but whether it is superior to the currently-available adjuvanted intramuscular formulations is, as-yet, unknown. The higher dose intradermal influenza vaccine indicated for older adults induces higher serological immune responses than the standard dose intramuscular vaccines to which it has been compared, similar responses as adjuvanted inactivated influenza vaccines, but lower responses than the high dose intramuscular inactivated influenza vaccine. The intradermal product is no longer available in Canada. Fluzone® High Dose and Intanza® (15µg) influenza vaccines induce higher rates of post-injection reactions, but these reactions are short-lived.

^b Fluzone High-Dose® was authorized for use in Canada in the Autumn of 2015.



VII. UPDATE TO THE REVIEW OF THE LITERATURE

Although anticipated, an intramuscular high dose seasonal influenza vaccine was not available on the market in Canada at the completion of the initial literature review. An update was conducted to ensure recommendations for the use of such a vaccine would be informed by a body of evidence that included the most current literature. The initial search strategy was replicated in Medline and EMBASE for literature indexed between June 27, 2014 and June 22, 2015. With the intradermal vaccine (Intanza®) no longer offered in Canada, studies using intradermal influenza vaccine as the high dose comparator were excluded.

The search yielded 1,003 non-duplicate records, with 73 articles undergoing full-text review. The review of the search results was conducted by two reviewers. Articles were only excluded if they were assessed as ineligible by both reviewers. If the first and second reviewers could not agree on the article's eligibility, the article was assessed by a third reviewer. Titles and abstracts, and full-text articles were screened for relevance and reasons for exclusion were the same as the initial review by two reviewers (see Methods section). Also excluded were articles that had previously been included in the review.

Two articles were subsequently selected for inclusion and were assessed for level of evidence (Appendix C, Table 1) and the quality of the study (Appendix C, Table 2). Appendix D contains extracted information on efficacy and effectiveness, and Appendix E on immunogenicity.

One study compared the relative efficacy of high dose vaccine and one assessed immunogenicity. Both are described below.

Izurieta et al. (2015) evaluated the relative efficacy of a high dose influenza vaccine [Fluzone® High Dose (60µg HA/strain)] and any standard dose influenza vaccine (15µg HA/strain) administered during the 2012-13 influenza season against probable influenza-related illness (community medical encounter with a rapid influenza diagnostic test and dispensing of oseltamivir), and hospital-in patient admission or emergency department visit with an influenza diagnosis⁶². The study participants included 2,545,275 community-based adults 65 years and older who were enrolled in Medicare in the United States. Fewer events were observed in recipients of the high dose vaccine for both outcomes and the relative efficacy was 22% in favour of the high dose vaccine for both outcomes (95% CI: 15, 29 for probable influenza-related illness, and 95% CI:16, 27 for hospitalization or emergency department visit). Relative efficacy for probable influenza-related illness increased to 36% (95% CI: 13, 54) in those 85 years and older.

Measures of immunogenicity were assessed in a study by Nace et al. (2015) comparing high dose influenza vaccine [Fluzone® High Dose (60µg HA/strain)] and a standard dose influenza vaccine (15µg HA/strain) in 187 frail adults 65 years and older residing in long-term care facilities over two influenza seasons (2011-12, 2012-13)⁶³. While comparable at baseline, at Day 30, GMTs were significantly higher in recipients of the high dose vaccine during both seasons, except for H1N1 in 2012-13 and seroprotection was significantly higher for H3N2 and B during both seasons. At Day 180, GMTs were only significantly higher for H3N2 and seroprotection was only higher for H1N1 and H3N2, during the 2011-12 season in high dose vaccine recipients.



15 | A REVIEW OF THE LITERATURE OF HIGH DOSE SEASONAL INFLUENZA VACCINE FOR ADULTS 65 YEARS AND OLDER

These two studies further support the conclusion of the original review that higher dose intramuscular, trivalent inactivated influenza vaccine for older adults should provide superior protection compared with the standard dose intramuscular vaccine. Izurieta et al (2015) demonstrates that this superior relative protection in older adults is enhanced in those 85 years and older. Nace et al. (2015) was also the first study to look at the use of high dose intramuscular influenza vaccine in a population of frail older adults, and begins to address an identified evidence gap. However, there continues to be a need for studies of high dose intramuscular trivalent inactivated influenza vaccine in high risk patients of all ages and for head-to-head trials of high dose intramuscular influenza vaccine, adjuvanted influenza vaccine, and the quadrivalent influenza vaccine.



VIII. LIST OF ABBREVIATIONS

Abbreviation Term

AE Adverse event
ADV Adjuvanted vaccine
ARI Acute respiratory illness

GMFR Geometric mean fold rise (post-vaccine GMT/pre-vaccine GMT)

GMT Geometric mean titre

GMTR Geometric mean titre ratio (post-vaccine GMT₁/post-vaccineGMT₀)

HI Haemagglutination inhibition

ID Intradermally-administered vaccine

ILI Influenza-like illness

IM Intramuscularly-administered vaccine LAIV Live attenuated influenza vaccine

SAE Serious adverse event

v Versus



IX. REFERENCES

- 1. Mitchell R, Taylor G, McGeer A, Frenette C, Suh KN, Wong A, et al. Understanding the burden of influenza infection among adults in Canadian hospitals: a comparison of the 2009-2010 pandemic season with the prepandemic and postpandemic seasons. Am J Infect Control. 2013 Nov:41(11):1032-1037.
- 2. McElhaney JE, Coler RN, Baldwin SL. Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults. Expert review of vaccines. 2013 Jul;12(7):759-766. Epub 2013/07/28.
- 3. Goodwin K, Viboud C, Lone S. Antibody response to influenza vaccination in the elderly: A quantitative review. Vaccine. 2006;24(8):1159-1169.
- 4. Grubeck-Loebenstein B, Della Bella S, Iorio AM, Michel JP, Pawelec G, Solana R. Immunosenescence and vaccine failure in the elderly. Aging-Clinical & Experimental Research. 2009 Jun;21(3):201-209.
- 5. McElhaney JE. Influenza vaccine responses in older adults. Ageing Research Reviews. 2011;10(3):379-388.
- 6. Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine. 2013 Dec 5;31(50):6030-6033. Epub 2013/10/08.
- 7. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2012 Jan;12(1):36-44.
- 8. World Health Organization. Influenza (seasonal) 2014 [updated 2014 Mar 2014 May 04]. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/
- 9. Nguyen-Van-Tam JS. Epidemiology of influenza. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza: Blackwell Science; 1998. p. 181-206.
- 10. Fleming DM, Elliot AJ. The impact of influenza on the health and health care utilization of elderly people. Vaccine. 2005;23(S1):S1-S9.
- 11. Schanzer DL, McGeer A, Morris K. Statistical estimates of respiratory admissions attributable to seasonal and pandemic influenza for Canada. Influenza and other respiratory viruses. 2013 Sep;7(5):799-808. Epub 2012/11/06.
- 12. Molinari N-AM. The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Vaccine. 2007;25:5086-5096.
- 13. Anonymous. FluWatch summary burden of illness in seniors. In: Coleman BL, editor. Ottawa, ON: Public Health Agency of Canada; 2014.
- 14. Schanzer DL, Sevenhuysen C, Winchester B, Mersereau T. Estimating influenza deaths in Canada, 1992-2009. PloS one. 2013 27 Nov;8(11).
- 15. Kwong JC, Stukel TA, Lim J, McGeer AJ, Upshur REG, Johansen H, et al. The effect of universal influenza immunization on mortality and health care use. PLoS Medicine. 2008 October;5(10):1440-1452.
- 16. Schanzer DL, Tam TWS, Langley JM, Winchester BT. Influenza-attributable deaths, Canada 1990-1999. Epidemiology and Infection. 2007 (135):1109-1116.
- 17. Schanzer DL, Langley JM, Tam TW. Co-morbidities associated with influenza-attributed mortality, 1994-2000, Canada. Vaccine. 2008 Aug 26;26(36):4697-4703. Epub 2008/07/16.
- 18. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. Morbidity and Mortality Weekly. 2008;57(RR-7):1-64.
- 19. Kwong JC, Rosella LC, Johansen H. Trends in influenza vaccination in Canada, 1996/1997 to 2005. Health reports. 2007 Nov;18(4):9-19. Epub 2007/12/14.



- 20. Public Health Agency of Canada. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) statement on seasonal influenza vaccine for 2014-2015. Ottawa, Ontario: Public Health Agency of Canada; 2014.
- 21. DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine. 2013 Jan 30;31(6):861-866.
- 22. DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty. J Am Geriatr Soc. 2014 March;62:S37-S38.
- 23. Keitel WA, Treanor JJ, El Sahly HM, Gilbert A, Meyer AL, Patriarca PA, et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old. Vaccine. 2009 Dec 11;28(2):379-385.
- 24. Centers for Disease Control and Prevention. Flublok seasonal influenza (flu) vaccination Atlanta, GA: Centers for Disease Control and Prevention; 2013 [updated 2013-Aug-08; cited 2014-2014-Aug-28]. Available from: http://www.cdc.gov/flu/protect/vaccine/qa_flublok-vaccine.htm
- 25. Puig-Barbera J, Natividad-Sancho A, Calabuig-Perez J, Lluch-Rodrigo JA, Pastor-Villalba E, Martinez-Ubeda S, et al. Intradermal and virosomal influenza vaccines for preventing influenza hospitalization in the elderly during the 2011-2012 influenza season: A comparative effectiveness study using the Valencia health care information system. Vaccine. 2014 Aug 12. Epub 2014/08/19.
- 26. European Agency for the Evaluation of Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines1997 02-February-2011. Available from: www.emea.europa.eu/pdfs/human/bwp/02149en.pdf
- 27. Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines Rockville, MD: US Department of Health and Human Services; 2007 [cited 2013]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091990.pdf
- 28. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009 Jul 15;200(2):172-180.
- 29. Couch RB, Winokur P, Brady R, Belshe R, Chen WH, Cate TR, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine. 2007 Nov 1;25(44):7656-7663.
- 30. Keitel WA, Atmar RL, Cate TR, Petersen NJ, Greenberg SB, Ruben F, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med. 2006 May 22;166(10):1121-1127.
- 31. Study of Fluzone® influenza virus vaccines 2012-2013 formulation among adults [Internet]. 2013 [cited 2014 July 14]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01361339
- 32. Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, et al. Immunogenicity and safety of Fluzone intradermal and high-dose influenza vaccines in older adults >65 years of age: A randomized, controlled, phase II trial. Vaccine. 2014 01 May;32(21):2507-2517.
- 33. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. The New England Journal of Medicine. 2014;371(7):635-645.



- 34. Martinez-Baz I, Martinez-Artola V, Reina G, Guevara M, Cenoz MG, Moran J, et al. Effectiveness of the trivalent influenza vaccine in Navarre, Spain, 2010-2011: a population-based test-negative case-control study. BMC Public Health. 2013;13:191.
- 35. U.S. National Institutes of Health. Cell mediated immunity in older adults (CMI). 2014.
- 36. Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, et al. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59® adjuvant: results from a dose-finding clinical trial in older adults. Human Vaccines & Immunotherapeutics. 2012;8(2):216-227.
- 37. Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, et al. A dose-range study in older adults to compare the safety and immunogenicity profiles of MF59-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration. Human Vaccines & Immunotherapeutics. 2014;10(6):1701-1710.
- 38. Cools HJ, Gussekloo J, Remmerswaal JE, Remarque EJ, Kroes AC. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial. J Med Virol. 2009 May;81(5):908-914.
- 39. Palache AM, Beyer WE, Sprenger MJ, Masurel N, de Jonge S, Vardy A, et al. Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine. 1993;11(1):3-9.
- 40. Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay CM, et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis. 2006 May 1;193(9):1223-1228.
- 41. Scheifele DW, McNeil SA, Ward BJ, Dionne M, Cooper C, Coleman B, et al. Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: Results of a randomized, controlled comparison. Human Vaccines and Immunotherapeutics. 2013 November;9(11):2460-2473.
- 42. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis. 2008 Sep 1;198(5):650-658.
- 43. Hoon Han S, Hee Woo J, Weber F, Joo Kim W, Ran Peck K, Il Kim S, et al. Immunogenicity and safety of Intanza®/IDflu® intradermal influenza vaccine in South Korean adults: a multicenter, randomized trial. Human Vaccines & Immunotherapeutics. 2013 Sep;9(9):1971-1977. Epub 2013/06/20.
- 44. Chan TC, Hung IF, Chan KH, Li CP, Li PT, Luk JK, et al. Immunogenicity and safety of intradermal trivalent influenza vaccination in nursing home older adults: a randomized controlled trial. Journal of the American Medical Directors Association. 2014 Aug;15(8):607 e605-607 e612. Epub 2014/06/25.
- 45. Seo YB, Choi WS, Lee J, Song JY, Cheong HJ, Kim WJ. Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly. Clinical and vaccine immunology: CVI. 2014 Jul;21(7):989-996. Epub 2014/05/16.
- 46. Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine. 2009 Dec 9;27(52):7304-7312.
- 47. Sibunruang S. Two-site intradermal influenza vaccination in elderly. Clinical Microbiology and Infection. 2011 May:17:S425-S426.
- 48. Camilloni B, Basileo M, Di Martino A, Donatelli I, Iorio AM. Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains. Immunity and Ageing. 2014 16 May;11(1).



- 49. Van Damme P, Arnou R, Kafeja F, Fiquet A, Richard P, Thomas S, et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infectious Diseases. 2010;10:134.
- 50. Ansaldi F, Orsi A, de Florentiis D, Parodi V, Rappazzo E, Coppelli M, et al. Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: evaluation of immunogenicity, cross-protection, safety and tolerability. Hum Vaccin Immunother. 2013 Mar;9(3):591-598. Epub 2013/01/09.
- 51. Abbott Laboratories Limited. Influvac® influenza vaccine, surface antigen, inactivated Product Monograph. 2014.
- 52. GlaxoSmithKline Inc. Fluviral® (2014-2015) influenza virus vaccine trivalent, inactivated split virion Product Monograph. 2014.
- 53. Sanofi Pasteur. Vaxigrip® inactivated influenza vaccine trivalent types A and B (split virion). Product Monograph 2013-2014. In: Pasteur S, editor.: Sanofi Pasteur Limited, Canada; 2013.
- 54. Sanofi Pasteur. IntanzaTM influenza vaccine (split virion, inactivated) product monograph. Toronto, Canada: 2010.
- 55. Sanofi Pasteur. Fluzone® High dose highlights of prescribing information. In: Pasteur S, editor. 2013.
- 56. Novartis. Fluad® influenza virus vaccine, surface antigen, inactivated, adjuvanted with MF59C.1 Product Monograph. 2014.
- 57. Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults [Internet]. U.S. National Institutes of Health. 2013 [cited August 2, 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01430819
- 58. Robertson CA, Greenberg DP, Decker MD. Safety and immunogenicity comparison of 2011-2012 high-dose and standard intramuscular influenza vaccines in older adults. IDWeek 2012; San Diego, CA: IDWeek; 2012.
- 59. Cell mediated immunity in older adults (CMI) [Internet]. U.S. National Institutes of Health. 2014 [cited August 2, 2014]. Available from:
- http://www.clinicaltrials.gov/ct2/show/NCT01189123
- 60. Roos-Van Eijndhoven DG, Cools HJ, Westendorp RG, Ten Cate-Hoek AJ, Knook DL, Remarque EJ. Randomized controlled trial of seroresponses to double dose and booster influenza vaccination in frail elderly subjects. J Med Virol. 2001 Apr;63(4):293-298.
- 61. Statistics Canada. Table 051-0001 Estimates of population, by age group and sex for July 1, Canada, provinces and territories, annual (persons unless otherwise noted), CANSIM (database). [cited: September 4, 2015].
- 62. Izurieta HS, Thadani N, Shay DK, Lu Y, Maurer A, Foppa IM, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infectious Diseases. 2015 Mar;15(3):293-300.
- 63. Nace DA, Lin CJ, Ross TM, Saracco S, Churilla RM, Zimmerman RK. Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities. Journal of Infectious Diseases. 2015 Jun; 211(12):1915-1924.



Appendix A: Search strategy and results

Set	History	Results	Comments
	MEDLINE		
1	([influenza* or flu or "caiv-t" or laiv or grippe or "h1n1" or "h3n2"] adj5 [vaccin* or inocul* or inject*]).mp.	23003	Influenza vaccine textword Terms
2	(admune or afluria or agrippal or agriflu or alorbat or adiugrip or berigripina or biaflu-zonale or celvapan or chiromas or evagrip or flu-imune or fluogen or fluvaccin or gripavac or grippe-impfstoff or grippeimpfstoff or imovax or inflexal or influenzainum or influmix or influpozzi or influsplit or influvac or influvirus or isiflu or miniflu or nasalflu or niligrip or prodigrip or sandovac or anflu or batrevac or begrivac or "flu immune" or "flu imune" or "flu-vac" or flulaval or fluvirin or fluzone or fluarix or alluria or fluad or fluarix or fluax or "adjufluax" or flublok or flucelvax or fluenz or flumist or fluinsure or "intranasal TIV" or flulaval or fluogen or flushield or fluvax or fluviral or fluvirin* or fluzone or gammaflu or grippovac or idflu or intanza or inflexal or influject or influpozzi or influsplit or influvac or intanza or invivac or mastaflu or "mfv ject" or munevan or mutagrip or niligrip or optaflu or preflucel or previgrip or trivalent or vacciflu or vaxigrip or "x-flu").mp.	5006	Specific vaccine textword Terms
3	(fluvax or Imuvac or Viroflu or Fluval or virosome or virosomal or Enzira or fluvirix or AS03 or MF59 or AS04 or virsomes).mp.	946	Specific vaccine textword Terms
4	Influenza Vaccines/	16309	Influenza Vaccines MeSH terms
5	orthomyxoviridae infections/ or influenza, human/	41942	Influenza Virus MeSH terms
6	influenzavirus a/ or influenza a virus/ or influenza a virus, h1n1 subtype/ or influenza a virus, h3n2 subtype/ or influenzavirus b/ or influenza b virus/	28418	Influenza Virus MeSH terms
7	or/1-6	64873	MEDLINE influenza vaccine or virus terms*
8	limit 7 to ("all aged [65 and over]" or "aged [80 and over]")	7844	Age group limit
9	nursing homes/ or Homes for the Aged/ or (aged or senior* or "older adult*" or geriatric or retired or retiree* or elder* or pensioner*).ti,ab.	561491	Aged MeSH or textword terms
10	8 or (7 and 9)	10017	Geriatric age group results - Base Clinical Set
11	(clinical trial, phase iii or clinical trial, phase iv or controlled clinical trial or meta analysis or multicenter study or randomized controlled trial or pragmatic clinical trial).pt. or clinical trials, phase iii as topic/ or clinical trials, phase iv as topic/ or controlled clinical trials as topic/ or randomized controlled trials as topic/ or pragmatic clinical trials as topic/ or multicenter studies as topic/ or observational study as topic/ or meta-analysis as topic/ or double-blind method/ or single-blind method/ or (rct or rcts or random* or multicent* or placebo* or metaanalysis* or "meta-analysis" or sham or effectiveness or efficacy or compare*).mp. or (meta adj5 analysis).mp. or ([singl: or doubl: or tripl: or trebl:) adj5 (mask:	3492788	Clinical Trial MeSH and Textword Terms



Set	History	Results	Comments
	or blind:]) mp.		
12	10 and 11	3982	Unique Clinical trial results
13	case-control studies/ or cohort studies/ or follow-up studies/ or longitudinal studies/ or prospective studies/ or retrospective studies/ or ([observational or evaluation or comparative] adj3 [study or studies or studied]).mp.	3167204	Cohort/Observati onal Study MeSH and textword terms
14	10 and 13	2732	Cohort study results
15	14 not 12	1154	Unique cohort results
	EMBASE		
1	([influenza* or flu or "caiv-t" or laiv or grippe or "h1n1" or "h3n2") adj5 (vaccin* or inocul* or inject*]).mp.	45225	Influenza vaccine textword Terms
2	(admune or afluria or agrippal or agriflu or alorbat or adiugrip or berigripina or biaflu-zonale or celvapan or chiromas or evagrip or flu-imune or fluogen or fluvaccin or gripavac or grippe-impfstoff or grippeimpfstoff or imovax or inflexal or influenzainum or influmix or influpozzi or influsplit or influvac or influvirus or isiflu or miniflu or nasalflu or niligrip or prodigrip or sandovac or anflu or batrevac or begrivac or "flu immune" or "flu imune" or "flu-vac" or flulaval or fluvirin or fluzone or fluarix or alluria or fluad or fluarix or fluax or "adjufluax" or flublok or flucelvax or fluenz or flumist or fluinsure or "intranasal TIV" or flulaval or fluogen or flushield or fluvax or fluviral or fluvirin* or fluzone or gammaflu or grippovac or idflu or intanza or inflexal or influject or influpozzi or influsplit or influvac or intanza or invivac or mastaflu or "mfv ject" or munevan or mutagrip or niligrip or optaflu or preflucel or previgrip or trivalent or vacciflu or vaxigrip or "x-flu").mp.	9190	Specific vaccine textword Terms
3	(fluvax or Imuvac or Viroflu or Fluval or virosome or virosomal or Enzira or fluvirix or AS03 or MF59 or AS04 or virsomes).mp.	1478	Specific vaccine textword Terms
4	influenza vaccination/ or influenza vaccine/	30200	Influenza Vaccines EMBASE terms
5	influenza/ or orthomyxovirus infection/ or seasonal influenza/	56842	Influenza Virus EMBASE terms
6	influenza virus/ or influenza a/ or 1977 russian influenza/ or 2009 h1n1 influenza/ or asian influenza/ or hong kong influenza/ or "influenza a (h1n1)"/ or "influenza a (h2n2)"/ or "influenza a (h3n2)"/ or influenza virus a h1n2/ or influenza virus a h2n2/ or influenza virus a h3n8/ or influenza virus b/ or influenza b/ or "influenza b virus (b/jing fang/76/98)"/	34222	Influenza Virus EMBASE terms
7	or/1-6	103871	EMBASE influenza vaccine or virus terms*
8	limit 7 to aged <65+ years>	8936	Age group limit
9	nursing home/ or nursing home patient/ or elderly care/ or exp geriatric care/ or home for the aged/ or (aged or senior* or "older adult*" or geriatric or retired or retiree* or elder* or pensioner*).ti,ab.	840992	Aged EMBASE or textword terms
10	8 or (7 and 9)	13301	Geriatric age



Set	History	Results	Comments
301		riosaito	group results -
			Base Clinical Set
11	limit 10 to (clinical trial or randomized controlled trial or	2223	Clinical Trial
	controlled clinical trial or multicenter study or phase 3 clinical		EMBASE limit
	trial or phase 4 clinical trial)		
12	limit 10 to (meta analysis or "systematic review")	165	Meta-analysis
13	clinical trial/ or controlled clinical trial/ or randomized	5442758	EMBASE limit Clinical Trial
10	controlled trial/ or multicenter study/ or phase 3 clinical trial/	3442730	EMBASE and
	or phase 4 clinical trial/ or meta analysis/ or "clinical trial		textword terms
	(topic)"/ or "controlled clinical trial (topic)"/ or "randomized		
	controlled trial (topic)"/ or "multicenter study (topic)"/ or		
	"phase 3 clinical trial (topic)"/ or "phase 4 clinical trial (topic)"/		
	or "meta analysis (topic)"/ or control group/ or crossover procedure/ or double blind procedure/ or single blind		
	procedure/ or triple blind procedure/ or (rct or rcts or random*		
	or multicent* or placebo* or metaanalysis* or "meta-analysis"		
	or sham or effectiveness or efficacy or compare*).mp. or		
	(meta adj5 analysis).mp. or ([singl: or doubl: or tripl: or trebl:]		
4.4	adj5 [mask: or blind:]).mp.	20.10	
14	11 or 12 or (10 and 13)	6349	Unique Clinical trial results
15	cohort analysis/ or observational study/ or comparative study/	1151928	Cohort/Observati
10	or comparative effectiveness/ or case control study/ or	1101020	onal Study
	hospital based case control study/ or population based case		EMBASE and
	control study/ or longitudinal study/ or postmarketing		textword terms
	surveillance/ or drug surveillance program/ or ([observational		
	or evaluation or comparative] adj3 [study or studies or		
16	studied]).mp. 10 and 15	1522	Cohort study
10	To dila 10	1022	results
17	16 not 14	534	Unique cohort
			results
	EBM reviews - Cochrane Central Register of Controlled Tri		
1	([influenza* or flu or "caiv-t" or laiv or grippe or "h1n1" or "h3n2"] adj5 [vaccin* or inocul* or inject*]).mp.	2187	Influenza vaccine textword Terms
2	(admune or afluria or agrippal or agriflu or alorbat or adiugrip	537	Specific vaccine
_	or berigripina or biaflu-zonale or celvapan or chiromas or	00.	textword Terms
	evagrip or flu-imune or fluogen or fluvaccin or gripavac or		
	grippe-impfstoff or grippeimpfstoff or imovax or inflexal or		
	influenzainum or influmix or influpozzi or influsplit or influvac		
	or influvirus or isiflu or miniflu or nasalflu or niligrip or		
	prodigrip or sandovac or anflu or batrevac or begrivac or "flu immune" or "flu imune" or "flu-vac" or flulaval or fluvirin or		
	fluzone or fluarix or alluria or fluad or fluarix or fluax or "adju-		
	fluax" or flublok or flucelvax or fluenz or flumist or fluinsure or		
	"intranasal TIV" or flulaval or fluogen or flushield or fluvax or		
	fluviral or fluvirin* or fluzone or gammaflu or grippovac or idflu		
	or intanza or inflexal or influject or influpozzi or influsplit or		
	influvac or intanza or invivac or mastaflu or "mfv ject" or		
	munevan or mutagrip or niligrip or optaflu or preflucel or previgrip or trivalent or vacciflu or vaxigrip or "x-flu").mp.		
		277	Specific vaccine
3	(fluvax or Imuvac or Viroflu or Fluval or virosome or virosomal	1 211	Specific vaccine



24 | A REVIEW OF THE LITERATURE OF HIGH DOSE SEASONAL INFLUENZA VACCINE FOR ADULTS 65 YEARS AND OLDER

Set	History	Results	Comments
	virsomes).mp.		
4	Influenza Vaccines/ or influenza vaccination/ or influenza vaccine/	1071	Influenza Vaccines MEDLINE and EMBASE terms
5	orthomyxoviridae infections/ or influenza, human/ or influenza/ or orthomyxovirus infection/ or seasonal influenza/	1049	Influenza Virus MEDLINE and EMBASE terms
6	influenzavirus a/ or influenza a virus/ or influenza a virus, h1n1 subtype/ or influenza a virus, h3n2 subtype/ or influenzavirus b/ or influenza b virus/ or influenza virus/ or influenza a/ or 1977 russian influenza/ or 2009 h1n1 influenza/ or asian influenza/ or hong kong influenza/ or "influenza a (h1n1)"/ or "influenza a (h2n2)"/ or "influenza a influenza virus a h1n2/ or influenza virus a h2n2/ or influenza virus a h3n2/ or influenza virus a h3n8/ or influenza virus b/ or influenza b/ or "influenza b virus (b/jing fang/76/98)"/	708	Influenza Virus EMBASE terms
7	Or/1-6	2724	MEDLINE, EMBASE and textword influenza vaccine or virus terms*
8	nursing homes/ or Homes for the Aged/ or nursing home/ or nursing home patient/ or elderly care/ or exp geriatric care/ or home for the aged/ or (aged or senior* or "older adult*" or geriatric or retired or retiree* or elder* or pensioner*).ti,ab.	46889	Age group terms
9	7 and 8	707	FINAL Results



Appendix B: Flow diagram


Title: A Review of the Literature of High Dose Seasonal Influenza Vaccine for Adults 65 Years and Older

Identification

Screening

Eligibility

Included





Appendix C: Level of evidence based on research design and quality (internal validity) rating of evidence

Table 1: Levels of Evidence Based on Research Design

	<u> </u>
I	Evidence from randomized controlled trial(s).
II-1	Evidence from controlled trial(s) without randomization.
II-2	Evidence from cohort or case—control analytic studies, preferably from more than one centre or research group using clinical outcome measures of vaccine efficacy.
II-3	Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence.
III	Opinions of respected authorities, based on clinical experience, descriptive studies and case reports, or reports of expert committees.

Table 2: Definition of overall study quality

Table 2. Definition of overall study quanty							
Good	A study (including meta-analyses or systematic reviews) that meets all design- specific criteria* well.						
Fair	A study (including meta-analyses or systematic reviews) that does not meet (or it is not clear that it meets) at least one design-specific criterion but has no known "fatal flaw".						
Poor	A study (including meta-analyses or systematic reviews) that has at least one design- specific "fatal flaw", or an accumulation of lesser flaws to the extent that the results of the study are not deemed able to inform recommendations.						
*General design specific criteria are outlined in Harris et al., 2001 ¹ .							



Appendix D: Summary of evidence related to efficacy/effectiveness of high dose influenza vaccines in adults 65 years and older

		(STUDY DETAILS		SUMN	IARY
Study	Vaccine	Study Design	Participants	Summary of Key Findings	Level of Evidence	Quality
Diaz Granados (2013) ²¹ NCT00976027	High-Dose (Sanofi Pasteur) 60µg HA/strain 0.5mL/dose 15µg: Fluzone® (Sanofi Pasteur) 15µg HA/strain 0.5mL/dose Strains A/Brisbane/59/0 7 (H1N1) A/Uruguay/716/ 2007 (H3N2) B/Brisbane/60/2 008	RCT Double-blind Multi-centre Phase 3b Country USA 99 centres Year 2009-10	Age ≥65 yrs Mean 72.8 yrs (64–99 yrs) Male 46.3% N=9158 60µg=6107 15µg=3051 85% Caucasian 89% vaccinated last season Ambulatory, medically stable Excluded Bed-ridden, Immune suppressing disease	Follow up: 7 months, during 2009pdm Outcome: ILI with lab-confirmed NP swab PCR-confirmed influenza (any subtype) Attack rates (per protocol) 15 v 60μg 2.66/1000 v 2.33/1000 Relative vaccine efficacy ILI 12.5% (-140.9,65.7) Notes: 21/22 cases were A/California/7/2009-like 24% of 60μg and 15μg participants received the H1N1 2009pdm vaccine respectively ILI defined as: ≥ 1 of temperature >37.2°C, feverishness, chills, tiredness, headaches or myalgia; and ≥ 1 of nasal congestion, rhinorrhoea, sore throat, cough, sputum production, wheezing, chest tightness, shortness of breath, or chest pain with breathing	Level 1	Good
Diaz Granados (2014) ³³ NCT01427309	60µg: Fluzone® High Dose 60µg HA/strain 0.5mL/dose 15µg: Fluzone® 15µg HA/strain 0.5mL/dose 2011-12 strains	RCT Double-blind Multicenter Phase 3b–4 Country USA, Canada 126 centres Year 2011-12	Age ≥65 yrs Mean: 73.3 yrs Male 43.4% N=31,983 60µg=15,990 15µg=15,993 95% Caucasian 74% previous	Follow-up: active weekly January-April 30 Outcome: ILI with lab-confirmed NP swab Lab-confirmed influenza Attack rates: (any subtype) 15 v 60µg ILI 1.9 v 1.4% ARI 2.4 v 2.0% Relative efficacy 60µg:15µg	Level 1	Good

	A/California/ 7/2009 (H1N1) A/Victoria/210/2 009 (H3N2) B/Brisbane/60/2 008 2012-13 strains A/California/7/20 09 (H1N1) A/Victoria/361/ 2011 (H3N2) B/Texas/6/2011	& 2012-13	vaccination 67% ≥ 1 chronic condition	ILI 24.2% (9.7,36.5) ^S ARI 18.3% (5.0,29.8) Notes: ILI: ≥1 of sore throat, cough, sputum production, wheezing, or difficulty breathing <i>and</i> ≥1 of temperature >37.2°C, chills, tiredness, headaches, or myalgia ARI: sneezing, nasal congestion, rhinorrhoea, sore throat, cough, sputum production, wheezing, or difficulty breathing		
Izurieta (2015) ⁶²	IM: Fluzone High-Dose (Sanofi Pasteur) (60µg HA/strain) IM: Standard- dose vaccine (15 µg HA/strain)	Retrospective cohort Country USA Year: 2012-2013	Community based adults, ≥65 years of age N=2,545,275 60µg=929,730 15µg=1,615,545 Participants had to meet Medicare enrollment, duration and survival criteria, and have received vaccine from a community pharmacy that vaccinated at least one other beneficiary with the alternative vaccine within two weeks of index	 Primary outcome: Probable episode of influenzarelated illness defined as a community medical encounter with provision of a rapid influenza diagnostic test, followed by therapeutic dispensing of oseltamivir within a 2-day period) Secondary outcome: Hospital in-patient admission or emergency department visit diagnosis of influenza Outcomes per 10,000 person-weeks (60μg v. 15μg) Primary: 1.01 v. 1.30 [risk difference: 0.29 (0.19, 0.38)] Secondary: 0.86 v. 1.10 [risk difference: 0.24 (0.17, 0.30)] Relative vaccine effectiveness (60 μg v. 15 μg): Primary: 22% (15, 29) Secondary: 22% (16, 27) Notes: Groups well balanced, with only substantial differences being noted in geographic region Effect estimates consistent whether from univariate or multivariate Poisson regression Relative VE for primary outcome increased to 36% (13, 54) for those aged ≥85yrs 	II-2	Good

			vaccination			
Keitel (2009) ²³ NCT00395174	45µg: FluBlok® (Protein Sciences Corp) ~45µg rHA/strain 0.5mL/dose Strains A/Wisconsin (H3N2) A/New Caledonia (H1N1) B/Ohio 15µg: Fluzone® (Sanofi Pasteur). 15µg HA/strain 0.5mL/dose Strains A/Wisconsin (H3N2) A/New Caledonia (H1N1) B/Malaysia	RCT Double-blind Multi-centre Phase 3 Country USA 7 centres Year 2006-07	Age ≥65 yrs Mean: 45µg 72.9 yrs 15µg 73.9 yrs Male 47% N=869 45µg N=436 15µg N=433 98% Caucasian 83% vaccinated last season Ambulatory, medically- stable, community dwelling	Follow-up 2006-2007 season Outcome: ILI with culture-confirmed nasal and throat swabs Lab-confirmed influenza Attack rates (any subtype) 15 v 45µg Culture 0.5 v 0.2% Serological 2.8 v 2.1%; Relative VE (computed) Culture 0.50 (0.01,9.56) Serological 0.79 (0.27,2.25) Either 0.74 (0.27,1.94) Notes: ILI: fever with cough and/or sore throat	Level 1	Good
Puig-Barberà (2014) ²⁵	ID: Intanza® (Sanofi Pasteur) 15µg HA/strain 0.1mL/dose IM: Inflexal-V® (Crucell) virosomal, subunit 15µg HA/strain	Retrospective cohort Country Spain 9 hospital service areas Year 2011-12	Age ≥65 yrs Mean: 76.7 yrs Male: 44.7% N=164,021 ID=101,963 IM= 62,058 87% vaccinated last season	Follow up Dec 2011–Mar 2012 Influenza-related hospitalization Rate/100,000 person-week ID v IM; RR(Cl _{95%}) All ages 8.8 v 13.9 0.64 (0.50,0.81) 65-69 yrs 1.9 v 6.0 0.31 (0.12,0.83) 70-74 yrs 5.9 v 8.8 0.67 (0.36,1.27) 75-79 yrs 10.4 v 15.5 0.67 (0.42,1.07) 80-84 yrs 12.9 v 20.1 0.64 (0.40,1.02) ≥85 yrs 16.0 v 23.4 0.68 (0.42,1.14)	Level II-2	Good

30 | A REVIEW OF THE LITERATURE OF HIGH DOSE SEASONAL INFLUENZA VACCINE FOR ADULTS 65 YEARS AND OLDER

0.5mL	/dose		Polatica officialization and ID-IM	
			Relative effectiveness ID:IM	
Strain	S	Excluded	Crude 36% (19,50)	
A/Cali	fornia/7/20	readmissions	Adjusted 33% (15,48)	
09 (H ⁻	1N1)	within 30 days,		
A/Per	th/16/2009	institutionalized,	Notes:	
(H3N2	2)	receipt of other	Influenza-related admission:	
, -	bane/60/2	influenza	Vaccine ≥15 days before hospitalization & one of:	
008	54110/00/2	vaccines	main discharge diagnosis of influenza advantage of the BOD and from the formula of the same o	
000		Vaccinos	admission with PCR-confirmed influenza	

Appendix E: Summary of evidence related to immunogenicity of high dose seasonal influenza vaccines in adults 65 years and older

STUDY DETAILS							
Study	Vaccine	Study Design	Participants	Summary of Key Findings	Level of Evidence	Quality	
Couch (2007) ²⁹ NCT00115531 NCT00170508 NCT00170482	60µg: Experimental 60µg HA/strain 0.5mL/dose IM 15µg: Fluzone® (Sanofi Pasteur) 15µg HA/strain 0.5mL/dose IM Strains A/New Caledonia/20/9 9 (H1N1), A/Wyoming/03/ 2003 (H3N2) B/Jiangsu/10/20 03	RCT Double blind Multi-site Phase II Country USA Year 2004-05 Stratified by receipt of influenza vaccine in same season	Age ≥65 Mean: 73-74 yrs Male 51% N=414 60µg=206 15µg=208 78% vaccinated in fall of 2004 (same season) 96% Caucasian	Follow-up 28 days Seroconversion 15 v 60μg A(H1N1) 23.6 v 51.5%* A(H3N2) 24.5 v 41.3* B 16.8 v 35.0* Seroprotection ≥1:32; 15 v 60μg A(H1N1) 48.1 v 62.6%* A(H3N2) 91.8 v 94.7 B 57.2 v 62.1 GMTR Significantly higher for 60μg, all strains* Notes: Same participants included in Chen et al. 2011	Level I	Good	
DiazGranados (2013) ²¹ NCT00976027	60µg: Fluzone® High-Dose (Sanofi Pasteur) 60µg HA/strain 0.5mL/dose 15µg: Fluzone® (Sanofi Pasteur) 15µg HA/strain 0.5mL/dose Strains A/Brisbane/59/0	RCT Double-blind Multi-centre Phase 3b Country USA 99 centres Year 2009-10	Age ≥65 yrs Mean 72.8 yrs (64–99 yrs) Male 46.3 % N=9158 60µg=6107 15µg=3051 85% Caucasian 89% vaccinated	Follow up 28 days Seroprotection 15 v 60μg A(H1N1) 87.4 (85.2,89.4) v 94.9 (93.9,95.9)* A(H3N2) 94.8 (93.2,96.1) v 97.3 (96.5,98.0)* B 84.5 (82.1,86.7) v 93.4 (92.2,94.4)* GMFR 60/15μg A(H1N1) 1.57 (1.44; 1.71)* A(H3N2) 1.74 (1.57; 1.94)* B 1.61 (1.48; 1.75)*	Level 1	Good	

	7 (H1N1) A/Uruguay/716/		last season Ambulatory,			
	2007 (H3N2) B/Brisbane/60/2 008		medically stable			
			Excluded Bed-ridden,			
			Immune			
			suppressing disease			
DiazGranados, (2014) ³³	60µg: Fluzone® high	RCT Double-blind	Age ≥65 yrs Mean 73.3 yrs	Follow-Up: 28 days	Level 1	Good
(2014)	dose (Sanofi	Multicenter	Male 43.4%	Seroprotection 15 v 60µg		
NCT01427309	Pasteur)	Phase IIIb-IV	l l manne e m	Year 1		
	60µg HA/strain 0.5mL/dose	Country	Immuno- genicity	A(H1N1) 94.2 (93.2,95.1) v 98.1 (97.5,98.6)* A(H3N2) 96.5 (95.6,97.2) v 99.2 (98.7,99.5)*		
	45	USA, Canada	subset	B 83.9 (82.3,85.3) v 91.6 (90.4,92.7)*		
	15µg: Fluzone® 15µg HA/strain	126 centres	Year 1	Year 2 A(H1N1) 93.3 (92.3,94.2) v 98.8 (98.3, 99.2)*		
	0.5mL/dose	Yr 1 2011-12	60µg=2375	A(H3N2) 95.0 (94.2,95.8) v 98.6 (98.2, 99.0)*		
	2011-12 strains	Yr 2 2012-13	15µg=2382	B 72.8 (71.1,74.4) v 86.2 (84.9, 87.4)*		
	A/California/		Year 2	GMFR 60:15μg		
	7/2009 (H1N1) A/Victoria/210/2		60µg=2879 15µg=2872	Year 1 A(H1N1) 1.8 (1.6,1.9)*		
	009 (H3N2)			A(H3N2) 2.0 (1.8, 2.1)*		
	B/Brisbane/60/2 008		95% Caucasian	B 1.4 (1.3,1.5)* Year 2		
			74%	A(H1N1) 1.8 (1.7,1.9)*		
	2012-13 strains A/California/7/2		previously vaccinated	A(H3N2) 1.8 (1.7,1.9)* B 1.6 (1.5,1.7)*		
	009 (H1N1)		67% ≥ 1	(,)		
	A/Victoria/361/ 2011 (H3N2)		chronic condition			
	B/Texas/6/2011					
Falsey (2009) ²⁸	60µg: Experimental	RCT Double-blind	Age ≥65 years (65-97)	Follow-up 28 days	Level I	Good
NCT0091053	TIV split-virus 60µg/strain 0.5mL/dose	Multi-centre Phase III	Mean 73 yrs Male 52%	Seroconversion % (Cl _{95%}) 15 v 60μg A(H1N1) 23.1 (20.2,25.6) v 48.6 (46.6,50.5) ^S A(H3N2) 50.7 (47.9,53.5) v 69.1 (67.3,70.9) ^S		

		Country USA	N=3876	B 29.9 (27.4.32.6) v 41.8 (39.8,43.7) ^N		
	15µg: Fluzone®	30 centres	60µg=2576			
	(Sanofi Pasteur)		15µg=1275	Seroprotection 15 v 60µg		
	15µg HA/strain	Year 2006-07		A(H1N1) 76.8 (74.3,79.1) v 89.9 (88.7,91.0)*		
	0.5mL /dose		82%	A(H3N2) 96.5 (95.3,97.4) v 99.3 (98.9,99.6)*		
			vaccinated	B 67.6 (64.9,70.2) v 79.3 (77.6,80.3)*		
	Strains		last season	07.10 (0.110,10.12) 1.7.0.0 (1.7.10,00.10)		
	A/New		79%	GMFR 60/15µg		
	Caledonia/20/9		underlying	A(H1N1) 1.7 (1.6,1.8) ^S		
	9 (H1N1)		condition	A(H3N2) 1.8 (1.7,2.0) ^S		
	A/Wisconsin/67/		Condition	B 1.3 (1.2,1.4) ^N		
			Madiaally	Б 1.3 (1.2,1.4)		
	2005 (H3N2)		Medically	Only and a \$ > 7.5		
	B/Malaysia/250		stable,	Cohort of ≥75 years of age		
	6/04		community	Seroconversion 15 v 60µg		
			dwelling	A(H1N1) 20.7 (17.1,24.8) v 46.8 (43.5,50.2)		
				A(H3N2) 15.2 (9.6,20.7) v 52.5 (47.7,57.2)		
				B 10.1 (5.0,15.2) v 25.4 (21.4,29.7)		
				GMT Ratio ≥75 ; 60:15µg		
				A(H1N1) 1.8 (1.7,2.0) ^S		
				A(H3N2) 1.8 (1.6,2.0) ^S		
				B 1.3 (1.2,1.4) ^N		
				Cohort with cardiopulmonary disease		
				Seroconversion 15 v 60µg		
				A(H1N1) 22.0 (19.3,24.8) v 48.4 (46.0,50.7)*		
				A(H3N2) 48.5 (45.5,52.2) v 68.5 (66.3,70.6)*		
				GMT ratio 60:15µg		
				A(H1N1) 1.8 (1.6,1.9) ^S		
				A(H3N2) 1.8 (1.7,2.0) ^S		
				B 1.3 (1.2,1.4) ^N		
Nace (2015) ⁶³	IM: Fluzone	RCT	Age: ≥65	Follow up: 30 and 180 (±14) days from baseline	1	Fair
, ,	High-Dose	Single blind	years			
NCT01654224	(Sanofi Pasteur)	15 community-	Mean: 86.7	GMT 60µg v. 15µg		
	(60µg	based LTCFs	(71% ≥85 yrs)	Year 1 – Day 0		
	HA/strain)	22304 2.0.0	Male: 32%	A(H1N1) 17.1 (11.3, 25.9) v. 16.6 (10.3, 26.7)		
	1 17 (301 (111)	Country USA	141010. 02/0	A(H3N2) 8.9 (6.5, 12.3) v. 7.3 (5.3, 10.0)		
	IM: Standard-	Country COA	N at 30 days	B 15.3 (10.3, 22.6) v. 11.6 (8.6, 15.5)		
		Voore: 2011	•	10.3 (10.3, 22.0) v. 11.0 (6.6, 15.5)		
	dose vaccine	Years: 2011-	=187	Veer 1 Day 20		
	(15 μg	2012 & 2012-	60µg = 89	Year 1 – Day 30		

HA/strain)	13	15µg =98	A(H1N1) 78.2 (45.1, 135.7) v. 27.4 (17,44.3)* A(H3N2) 26.2 (17.1, 40.0) v. 10.2 (7.0, 14.8)*
		Frail and residing in LTCFs	B 25.6 (18.7, 34.9) v. 14.3 (11.1, 18.4)* Year 1 – Day 180
		110.0	A(H1N1) 59.7 (33.5, 106.3) v. 28.3 (15.3, 52.4) A(H3N2) 22.3 (14.5, 34.3) v. 9.4 (6, 14.8)* B 22.9 (16.3, 32) v. 15.4 (11.8, 20.2)
			Year 2 - Day 0 A(H1N1) 23.6 (16.7, 33.4) v. 32.3 (23.8, 43.9) A(H3N2) 7.2 (6.1, 8.3) v. 6.2 (5.4, 7.1) B 7.9 (6.5, 9.5) v. 9.1 (7.5, 11)
			Year 2 - Day 30 A(H1N1) 45.6 (32.9, 63.2) v. 50.0 (37.4, 67) A(H3N2) 23.4 (17.6, 31) v. 14.2 (11.0, 18.4)* B 26.0 (21.2, 31.9) v. 17.4 (13.9, 21.9)*
			Year 2 - Day 180 A(H1N1) 46.8 (33.2, 65.9) v. 51.8 (37.8, 71.1) A(H3N2) 24.7 (18.3, 33.2) v. 13.4 (10.3, 17.5)* B 25.3 (20.8, 30.9) v. 18.9 (14.9, 23.9)
			Seroprotection (%) 60μg v. 15μg Year 1 – Day 0 (n=31 v. 33) A(H1N1) 32.3 v. 36.4 A(H3N2) 6.5 v. 6.1 B 25.8 v. 15.2
			Year 1 – Day 30 (n=31 v. 33) A(H1N1) 71.0 v. 51.5 A(H3N2) 45.2 v. 18.2* B 45.2 v. 21.2*
			Year 1 - Day 180 (n=26 v. 24) A(H1N1) 76.9 v. 45.8* A(H3N2) 42.3 v. 12.5* B 23.1 v. 4.2

Sanofi Pasteur (2013) ⁵⁷ Robertson (2012) ⁵⁸ NCT01430819	60µg: Fluzone® High-Dose (Sanofi Pasteur) 60µg HA/strain 0.5mL/dose 15µg:Fluzone® (Sanofi Pasteur) 15µg HA/strain 0.5mL/dose Strains A/California/07/2009 (H1N1) A/Victoria/210/2 009 (H3N2) B/Brisbane/60/2 008	RCT Double-blind Multi-centre Phase IV Country USA 6 centres Year 2011-12	Age ≥ 65 yrs Mean 72.1 yrs Male: 39% N=300 60µg=145 15µg=147 96% Caucasian	Year 2 − Day 0 (n=58 v. 65) A(H1N1) 44.8 v. 53.8 A(H3N2) 3.4 v. 4.6 B 8.6 v. 6.2 Year 2 − Day 30 (n=58 v. 65) A(H1N1) 58.6 v. 72.3 A(H3N2) 51.7 v. 24.6* B 48.3 v. 29.2* Year 2 − Day 180 (n=53 v. 59) A(H1N1) 47.2 v. 52.5 A(H3N2) 52.8 v. 39.0 B 32.1 v. 33.9 Follow up 21 days Seroconversion 15 v 60μg A(H1N1) 36 (28,44) v 61 (53,69) A(H3N2) 41 (33,49) v 69 (61,76) B 22 (15,29) v 41 (33,50) Seroprotection (≥1:40) 15 v 60μg A(H1N1) 94 v 97 A(H3N2) 99 v 100 B 80 v 88 ≥1:160 15 v 60μg A(H1N1) 71 v 86 A(H3N2) 82 v 95 B 28 v 39 GMTR 15 v 60μg A(H1N1) 3.3 (2.7,4.0) v 7.1 (5.6,9.1) A(H3N2) 3.5 (2.9,4.2) v 8.2 (6.4,10.5) B 2.1 (1.9,2.4) v 3.1 (2.7,3.7)	Level 1	Good
Talbot (2014) ⁵⁹	60µg: Fluzone® High-Dose	RCT Double-blind	Age 67-79 yrs Mean 73 yrs	Follow-up 2 years	Level 1	Good
NCT01189123	(Sanofi Pasteur) 60μg HA/strain 0.5mL/dose	Single centre Country	Male 51.4% N=105	GMT 15 v 60μg A(H1N1) 40 (10,80) v 80 (40,140) A/H3H2 20 (20,40) v 80 (10,160)		Small sample size

	15µg: Fluzone® (Sanofi Pasteur) 15µg HA/strain 0.5mL/dose Strains not stated	USA Years: not stated	60µg=47 15µg=50	B 40 (20,80) v 40 (40,80) Notes: CD4+ and CD8+ data not abstracted		
Tsang (2014) ³² NCT00551031	60IM: High Dose IM15 (Sanofi Pasteur) 60µg/strain 0.5mL IM ID15: (Sanofi Pasteur) 15µg/strain 0.1 mL/dose ID 21ID: (Sanofi Pasteur) 21µg/strain 0.1 mL/dose ID 15IM: FluZone® (Sanofi Pasteur) 15µg/strain 0.5mL/dose IM Strains A/Solomon Islands/3/2006 (H1N1) A/Wisconsin/67/ 2005 (H3N2) B/Malaysia/250 6/2004	RCT Open label for route Double-blind for dose Multi-centre Phase II Country USA 31 centres Year 2007-08	Age 47-99 yrs Mean 73 yrs Male 44% N=1912 60µg IM=319 15µg ID=635 21µg ID=635 87% previously vaccinated 94% Caucasian Medically stable Ambulatory	Follow-up 28 days 60 vs 15μg IM Seroconversion Difference in rates (60-15μg) A(H1N1) 19.7 (12.8,26.6) A(H3N2) 16.8 (9.2,24.5) B 16.4 (10.7,22.1) Seroprotection Difference in rates (60-15μg) A(H1N1) 13.6 (8.4,18.8) A(H3N2) 1.9 (-0.2,4.0) B 15.6 (8.5,22.7) GMTR ratios (60/15IM) A(H1N1) 2.1 (1.7,2.6)* A(H3N2) 1.8 (1.5,2.1)* B 1.4 (1.2,1.6)* 60IM vs 15ID Seroconversion Difference in rates (60IM-15ID) A(H1N1) 9.2 (3.6,14.7) A(H3N2) 13.7 (7.0,20.4) B 10.5 (5.0,16.1) Seroprotection Difference in rates A(H1N1) 5.7 (2.0,9.5) A(H3N2) 1.0 (-0.6,2.5) B 12.4 (6.4,18.3) GMTR (60IM/15ID) A(H1N1) 1.4 (1.2,1.6)* A(H3N2) 1.4 (1.2,1.6)* B 1.3 (1.2,1.5)*	Level 1	Good
				60IM vs 21ID Seroconversion Difference in rates (60IM-21ID)		

				A(H1N1) 6.3 (0.8,11.8)		
				A(H3N2) 13.1 (6.4,19.8)		
				B 10.2 (4.6,15.7)		
				Seroprotection Difference in rates		
				A(H1N1) 3.7 (0,7.3)		
				A(H3N2) 1.6 (0,3.3)		
				B 10.6 (4.7,16.6)		
				GMTR (60IM/21ID)		
				A(H1N1) 1.3 (1.1,1.5)*		
				A(H3N2) 1.3 (1.1,1.5)*		
				B 1.2 (1.1,1.4)*		
				, ,		
				15ID vs 15IM		
				Seroconversion Difference in rates (ID-IM)		
				A(H1N1) 10.5 (4.1,16.9)		
				A(H3N2) 3.5 (-3.0,10.1)		
				B 5.8 (1.7,10.0)		
				GMTR (15ID/15IM)		
				A(H1N1) 1.50 (1.3,1.8) ^S A(H3N2) 1.23 (1.1,1.4) ^S		
				A(H3N2) 1.23 (1.1,1.4) ^S		
				B 1.04 (0.9,1.2) ^N		
				, ,		
				21ID vs 15IM		
				Seroconversion Difference in rates (ID-IM)		
				A(H1N1) 13.4 (7.0,19.8)		
				A(H3N2) 4.2 (-2.4,10.8)		
				B 6.2 (2.0,10.4)		
				GMTR (21ID/15IM)		
				A(H1N1) 1.6 (1.4,1.9) ^S		
				A(H3N2) 1.3 (1.2,1.5) ^S		
				B 1.1 (1.0,1.2) ^N		
Intramuscular,	Other					
Della Cioppa	IM15: 15μg	RCT	Age ≥65 yrs	Follow-up 22 days	Level 1	Good
(2012)	HA/strain	Observer-blind	Mean 69 yrs	. ,		
Della Cioppa	0.5mL/dose	Multicenter	Male 40-68%	Seroconversion A(H3N2) only		
(2014) ³⁷	no adjuvant			IM15 v IM30 70 v 63		Small
· - /	1,	Countries	N=450	ADV15 v ADV30 87 v 95		sample
NCT00848848	IM30: 30µg	Poland	IM15=43	ID6 v ID12 77 v 71		size

ea. 8. E. 0.5. no. AD Flu (No. 15) 0.5. 100 AD H3 ea. 8. E. 0.5. 100 HA 0.2 ID H3 ea. 8. E. 0.2 Str. A/E. 200 A/U /20	5mL/dose adjuvant DV15: uad® ovartis) pg/strain 5mL/dose 0% of MF59 DV30: 30µg BN2 & 15µg ch of H1N1 B 5mL/dose 0% of MF59 6: 6µg A/strain 2mL/dose 12: 12µg BN2 & 6µg ch of H1N1 B; 2mL/dose rains Brisbane/59/ 07 (H1N1) Uruguay/716 D07 (H3N2) Florida/4/20	Belgium Germany Year 2008-09	IM30=43 ADV15=46 ADV30=42 ID6=43 ID12=46 (other groups excluded) 73-81% previously vaccinated Healthy volunteers Excluded impaired immune system	Seroprotection		
Keitel (2006) ³⁰ 60 sul	µg: bvirion TIV ventis	RCT Single-center	Age ≥65 years Mean 72.4 yrs (65-88 yrs)	Follow up 28 days Seroconversion 15 v 30 v 60µg	Level 1	Good

	Pasteur) 60µg HA/strain 0.5mL/dose 30µg: subvirion TIV (Aventis Pasteur) 30µg HA/strain 0.5mL/dose 15µg: subvirion TIV (Aventis Pasteur) 15µg HA/strain 0.5mL/dose Placebo: saline Strains A/NewCaledon ia/20/99 (H1N1) A/Panama/200 7/99 (H3N2) B/Victoria/504/ 2000	Country USA Year 2001-02	Male 59 % N=202 60µg=50 30µg=51 15µg=51 Saline=50 97% Caucasian 82% vaccinated last season Ambulatory, medically stable .	A(H1N1) 17.6 v 31`.4 v 38.0 A(H3N2) 21.6 v 27.5 v 32.0 B 23.5 v 21.6 v 42.0 Seroprotection ≥1:32 Dose-related increases for all subtypes GMFR Significant differences for all subtypes (p<0.01) Dose-related increases for all subtypes		Small sample size Same antigens as previous season
60µg "experi	mental" Sub unit Ir	ntramuscular	1	1	l	
Palache (1993) ³⁹	60µg: Experimental trivalent subunit (Duphar BV) 60µg HA/strain 0.5mL/dose 10µg: 10µg HA/strain	RCT Double-blind Multi-centre Placebo- controlled Country Netherlands Israel	Data for 65+ yrs Age 68-99 yrs Mean 80 yrs N=262 60µg=66 10µg=67 20µg=64 Saline=65	Follow-up 21 days Seroconversion N/A Seroprotection (≥1:100 for A; ≥1:200 for B) 10 ∨ 20 ∨ 60μg A(H1N1) 33 ∨ 33 ∨ 42 A(H3N2) 72 ∨ 75 ∨ 80 B 52 ∨ 67 ∨ 77	Level 1	Good Small sample size

Recombinant V	20µg: 20µg HA/strain Experimental trivalent subunit Saline/placebo 0.5mL/dose Strains A/Taiwan/2/86 (H1N1) A/Sichuan/2/8 7 (H3N2) B/Beijing/1/87	Year 1988 See Remarque (1993) for same participants – for IgG, IgA, IgM responses to H3N2 strain	22% previously vaccinated Nursing home residents Excluded Immune suppressing drug treatment	GMFR 20/10μg v 60/10μg A(H1N1) No dose response effect A(H3N2) 1.3 v 1.6 B 1.4 v 2.1		
Keitel (2009) ²³	FluBlok®	RCT	Age ≥65 yrs	Follow-up: 28 days	Level 1	Good
Reilei (2009)	(Protein	Double-blind	Mean	Follow-up. 20 days	Level	Good
	Sciences	Multi-centre	45µg 72.9 yrs	Seroconversion 15 v 45µg		Different
NCT00395174	Corp.)	Phase 3	15µg 73.9 yrs	A(H1N1) 33(28,37) v 43(39,48) ^N		B strains
	~45µg		Male 47%	A(H3N2) 58(53,62) v 78(74,82) ^N		in
	rHA/strain	Country	N. 000 (-II)	B/Ohio 39(34,44) v 29(25,34)		vaccines
	0.5mL/dose	USA	N=869 (all)	B/Malaysia 10(7,12.8) v 20(16,23.5)		
	(Total: 131µg)	7 centres	45μg=431 15μg=430	Seroprotection 15 v 45µg		
	Strains	Year 2006-07	10μ9-400	A(H1N1) 95(92,97) v 95(92,97)		
	A/Wisconsin	1001 2000 01	≥75 years	A(H3N2) 93(90,95) v 97(94,98)		
	(H3N2)		45µg=163	B/Ohio 97(95,99) v 92(89,94)		
	A/New		15µg=159	B/Malaysia 30(26,34) v 40(35,45)		
	Caledonia			OUED (OL.) 45 45		
	(H1N1) B/Ohio		000/ Causasian	GMFR (Cl ₉₅) 15:45µg		
	B/OHIO		98% Caucasian 83% vaccinated	A(H1N1) 0.84 (0.81, 0.86) ^N A(H3N2) 0.59 (0.57, 0.60) ^N		
	15µg:		last season	B/Ohio 1.30 (1.26, 1.34) ^N		
	Fluzone®			B/Malaysia 1.37 (1.0, 1.7)		
	(Sanofi		Ambulatory,			
	Pasteur).		medically-	Seroconversion 45µg v 15µg		
	15µg HA/strain		stable,	A(H1N1) 43(39,48) v 33(28,37)*N		
	0.5mL/dose		community dwelling	A(H3N2) 78(74,82) v 58(53,62)* ^N B/Ohio 29(25,34) v 39(34,44)		

	Strains A/Wisconsin (H3N2) A/New Caledonia (H1N1) B/Malaysia			B/Malaysia $10(7,13) \vee 20(16,23)$ Cohort of ≥75 years Seroprotection $15\mu g \vee 45\mu g$ A(H1N1) $94(91,98) \vee 91(87,96)$ A(H3N2) $93(89,97) \vee 96(93,99)$ B/Ohio $99(98,100) \vee 96(93,99)$ B/Malaysia $31(24,38) \vee 47(39,54)$ GMFR $15:45\mu g$ A(H1N1) $0.82 (0.79, 0.85)^N$ A(H3N2) $0.59 (0.58, 0.61)^N$ B/Ohio $1.21 (1.18, 1.24)^N$ B/Malaysia $1.40 (1.1, 1.7)$		
Treanor (2006) ⁴⁰	Baculovirus- expressed (rHA) 135µg rHA/strain 45µg rHA/strain 15µg rHA/strain 0.5mL/dose IM15: Fluzone® (Sanofi Pasteur). 15µg HA/strain 0.5mL/dose Strains A/Panama/200 7/99 (H3N2) A/NewCaledon ia/20/99 (H1N1) B/HongKong/3 30/2001	RCT Double-blind Country USA Year not stated (2002-03 or 2003-04)	Age 65-90 yrs Mean: 72 yrs 49% male N=399 135rHA=101 45rHA=98 IM15=98 96% Caucasian Community- dwelling, medically stable	Follow-up 28 days Seroconversion IM15 v 15 v 45 v 135rHA A(H1N1)	Level 1	Good

Cools (2009) ³⁸	30µg : 15µg	RCT	Age 96% were	Follow-up: 25, 84, 109 days	Level 1	Good
Roos-van	HA/strain	Multi-centre	≥65 years	DATA for A(H3N2) strain only	207011	0000
Eijndhoven	0.5mL/dose x 2		Median 83-84	Seroconversion 15 v 30µg		
(2001) ⁶⁰	doses (same	Country:	Male 25%	Day 25 33.3 v 45.3*		
(====)	arm) Split virion	Netherlands		Day 84 28.6 v 37.1*		
	(Pasteur Mérieux	() 14 nursing	N=815	Day 106 27.1 v 35.4		
	,	homes	30μg (15*2)			
	15µg : 15µg		Day 25=360	Seroprotection 15 v 30µg		
	HA/strain	Year 1997-98	Day 84=340	Day 25 66.3 v 73.3*		
	0.5mL/dose Spli	t	Day106=155	Day 84 61.2 v 67.6		
	virion (Pasteur		'	Day 106 63.9 v 64.6		
	Mérieux)		15µg	·		
			Day 25=347	GMT 15 v 30μg		
			Day 84=325	Day 25 57.8 (49.2,68.2) v 70.6 (61.1,81.7)		
	Strains:		Day106=158	Day 84 48.6 (41.1,56.9) v 53.5 (45.9,61.9)		
	A/Nanchang/933	/		Day 106 49.3 (39.5,61.9) v 46.9 (37.6,58.8)		
	95 (H3N2),		39% previously			
	A/Johannes-		vaccinated	Notes: Significantly greater rates of seroprotection and		
	burg/82/96			seroconversion at Day 25 & 84 for participants with pre-		
	(H1N1), and		Long-term care	vaccination titres of <1:40 (only at Day 25 for ≥1:40)		
	B/Harbin/7/94		residents	Data regarding 'booster' doses not abstracted		
15µg Intraderm	nal					
Arnou (2009) ⁴⁶	ID:(Sanofi	RCT	Age 60-95 years	Follow-up: 21 days post vaccination	Level I	Good
	Pasteur;	Open-label	Mean 71 years			
NCT00383526	experimental)	Multi-centre	Male 20%	First vaccination 2006		
	15ug HA/strain			GMT non-inferior for all 3 strains (ID vs IM)		
	0.1mL/dose	Country:	N=3707	Seroprotection superior for all 3 strains (ID vs		
		France,		IM)		
	15IM:	Belgium,	Year 1	GMTR All 3 strains ID significantly higher		
	Vaxigrip®	Lithuania, Italy	ID=2604	(p<0.0001) than IM		
	(Sanofi		IM=1081	Seroconversion ID significantly higher (p<0.001)		
	Pasteur)	Years	V0	than IM		
	15ug HA/strain	2006-2009	Year 2	Second Vaccination 2007		
	0.5mL/dose		ID→ID =133	Second Vaccination 2007		
	Ctroins as		IM→IM =143	Seroconversion ID→ID v IM→IM		
	Strains as recommended		Year 3	A(H1N1) 74.2 (65.9,81.5) v 63.6 (55.2,71.5) A(H3N2) 36.6 (28.4,45.5) v 40.1 (32.0,48.7)		

	for		ID→ID→ID=121	B 14.3 (8.8,21.4) v 9.8 (5.5,15.9)		
	2006-2007		IM→IM→IM=67	Seroprotection ID→ID v IM→IM		
	2007-2008			A(H1N1) 95.5 (90.4,98.3) v 81.8 (74.5,87.8)		
	2008-2009			A(H3N2) 98.5 (94.6,99.8) v 95.8 (91.0,98.4)		
			65% chronic	B 55.6 (46.8,64.2) v 53.1 (44.6,61.5)		
	*Analysis includes		condition	GMFR ID→ID v IM→IM		
	only participants			A(H1N1) 9.64 (7.70,12.1) v 7.24 (5.82,9.02)		
	vaccinated with		Excluded	A(H3N2) 2.92 (2.43,3.51) v 2.88 (2.43,3.41)		
	the same vaccine		congenital or	B 1.77 (1.57,2.00) v 1.67 (1.50,1.86)		
	sequentially		acquired			
			immuno-	Third Vaccination 2008		
			deficiency	Seroconversion $ID\rightarrow ID\rightarrow ID \vee IM\rightarrow IM\rightarrow IM$		
				A(H1N1) 37.2 (28.6,46.4) v 31.8 (20.9,44.4)		
				A(H3N2) 73.6 (64.8,81.2) v 60.6 (47.8,72.4)		
			10 > 10 + 10	B 47.1 (38.0,56.4) v 26.9 (16.8,39.1)		
			ID→ID signifies ID injection in first year	Seroprotection $ID \rightarrow ID \rightarrow ID \lor IM \rightarrow IM \rightarrow IM$		
			followed by ID in	A(H1N1) 81.8 (73.8,88.2) v 74.2 (62.0,84.2)		
			second year	A(H3N2) 92.6 (86.3,96.5) v 77.3 (65.3,86.7)		
				B 70.2 (61.3,78.2) v 55.2 (42.6,67.4)		
				GMFR $ID\rightarrow ID\rightarrow ID \vee IM\rightarrow IM\rightarrow IM$		
				A(H1N1) 2.88 (2.43,3.41) v 2.86 (2.31,3.54)		
				A(H3N2) 8.45 (6.79,10.5) v 6.94 (5.15,9.36)		
				B 3.76 (3.16,4.46) v 2.40 (1.93,2.98)		
Chan (2014) ⁴⁴	ID: Intanza®	RCT	Age: ≥65 years	Follow-up: 21 days	Level I	Good
NOT04007000	(Sanofi	Open-label	Mean 83 years			
NCT01967368	Pasteur)	Single center	Male 36%	Day 21		
	15µg HA/strain	0	Tatalia 400	Seroconversion ID v IM		
	0.1mL/dose	Country:	Total: n=100 ID=50	A(H1N1) 60 v 36*		
	IM: Vaxigrip®	China (Hong	IM=50	A(H3N2) 30 v 16 B 20 v 22		
	(Sanofi	Kong)	IIVI=30	Seroprotection ID v IM		
	Pasteur)	Year 2013-14	Nursing home	A(H1N1) 96 v 90		
	15µg HA/strain	Cal 2013-14	residents	A(H3N2) 96 v 98		
	0.5mL/dose		TESIUETILS	B 98 v 94		
	U.JIIIL/UUSE			GMT ID v IM		
	Strains			A(H1N1) 8.6 (5.1,12.1) v 5.2 (2.4,7.9)		
	A/California/7/			A(H3N2) 2.7 (1.9,3.5) v 2.3 (1.0,3.5)		
	2009 (H1N1),			B 4.9 (1.4,8.4) v 2.0 (1.6,2.4)		
	A/Victoria/361/			GMTR IM/ID		
		ı	1			

	2011 (H3N2) B/Massachus- etts/2/2012			A(H1N1) 0.85 (0.55,1.01) A(H3N2) 0.60 (0.47,0.65) B 0.28 (0.40,1.13) Day 180 Seroconversion ID v IM A(H1N1) 38 v 22 A(H3N2) 16 v 2* B 20 v 6 Seroprotection ID v IM A(H1N1) 82 v 78 A(H3N2) 96 v 98 B 90 v 86 GMT ID v IM A(H1N1) 3.8 (2.3,5.3) v 2.6 (1.8,3.3) A(H3N2) 2.0 (1.4,2.7) v 1.2 (0.9,1.5)* B 2.4 (1.6,3.2) v 1.4 (0.0,1.8)*		
Hoon Han (2013) ⁴³ NCT01215669	ID: Intanza® (IDflu) 15µg HA/strain 0.1mL/dose IM: Vaxigrip® (Sanofi Pasteur) 15µg HA/strain 0.5 mL/dose Strains A/California/7/ 2009 (H1N1) A/Perth/16/200 9 (H3N2) B/Brisbane/60/ 2008	RCT Open-label Multicentre Phase IV Country South Korea 6 sites Year 2010-11	Age: 18+ years Data for ≥60 years Mean 64.5-64.9 yrs Male 38% N: 120 ID=60 IM= 60 38% vaccinated past year	Data in figures only CHMP criteria for all three strains met for ID and IM vaccines No statistically significant differences in rates of seroprotection, seroconversion, or for GMTR for ID and IM vaccines	Level I	Fair- Good (limited data could be abstract ed)
Holland (2008) ⁴²	15ID: 15µg HA/strain 21ID: 21µg	RCT Open label for route	Age 65-85 yrs Males 47%	Follow-up 21 days Seroconversion	Level I	Good

NCT00296829	HA/ strain Intradermal split-virion (Sanofi Pasteur) 0.1mL/dose 15IM: 15µg HA/strain VaxiGrip® (Sanofi Pasteur) 0.5mL/dose Strains A/New Caledonia/20/ 99 (H1N1) A/Wellington/1 /2004 (H3N2) B/Jiangsu/10/2 003	Double blind for dose Multicenter Phase II Country New Zealand Australia Year 2006	Total n=1101 15ID=366 21ID=369 15IM=366 ~85% vaccinated previous season Medically stable	Significantly higher (p<0.05) in the ID than in the IM, for all strains and both strengths Seroprotection A(H1N1) no difference A(H3N2) significantly higher for ID vs IM B significantly higher for ID vs IM GMTR 15ID/15IM & 21ID/15IM A(H1N1) 1.52 (1.28,1.78) ^S & 1.59 (1.36,1.84) ^S A(H3N2) 1.70 (1.41,2.04) ^S & 1.70 (1.42,2.03) ^S B 1.49 (1.27,1.74) ^S & 1.40 (1.20,1.64) ^S Notes: The 21µg ID vaccine did not induce a statistically significant difference in responses compared with the 15µg ID vaccine		
Seo (2014) ⁴⁵	ID: (Sanofi Pasteur) 15µg HA/strain 0.1mL/dose Comparator IM15: Aggripal S1® (Novartis) 15µg HA/strain 0.1mL/dose ADV: Fluad® (Novartis) 15µg HA/strain 0.1mL/dose adjuvant	RCT Multicenter Country South Korea	Age ≥65 years Median 71-73 years Male 32-39% N=335 IM15 =113 ADV=111 ID =111 Community-dwelling Good health	28 day follow-up Seroconversion ID v IM15 v ADV A(H1N1) 42.5 (34, 52) v 38.7 (30,49) v 54.1 (45,63) A(H3N2) 43.2 (34.2,54.3) v 26.5 (18.6,34.5) v 45.0 (36.0,54.1) B 7.2 (2.7,12.6) v 1.8 (0,4.4) v 7.2 (2.7,11.7) Seroprotection ID v IM15 v ADV A(H1N1) 78.8 (71.7,86.7) v 72.1 (63.1,80.2) v 84.7 (78.4,91.0) A(H3N2) 83.8 (75.7,91.0) v 71.7 (63.7,79.6) v 89.2 (82.9,94.6) B 18.6 (12.4,25.7) v 18.0 (10.8,25.2) v 24.3 (17.1,33.3) GMTR ID v IM15 v ADV A(H1N1) 3.6 (2.3,5.6) v 3.5 (2.2,5.7)	Level I	Good

	Year 2011-12 Strains A/California/7/ 2009 (H1N1) A/Perth/16/200 9 (H3N2) B/Brisbane/60/ 2008			V 4.4 (2.7,6.3) A(H3N2) 3.5 (2.4,5.2) v 1.9 (1.3,2.8) v 3.4 (2.2,5.2), B 1.4 (1.0,1.9) v 1.2 (0.8,1.6) v 1.6 (1.1,2.4) 180 day follow-up Seroconversion A(H1N1) 8.8 (3.5,15.0) v 10.8 (5.4,17.1) v 5.4 (1.8,9.9) A(H3N2) 34.2 (25.2,43.2) v 37.8 (27.9,47.7) v 28.3 (20.4,37.2) B 1.8 (0,4.5) v 1.8 (0,4.5) v 2.7 (0,5.3) Seroprotection A(H1N1) 53.1 (44.2,61.9) v 51.4 (42.3,61.3) v 37.8 (28.8,46.8) A(H3N2) 74.8 (66.7,82.9) v 77.5 (70.3,84.7) v 64.6 (56.6,73.5) B 18.6 (12.4,25.7) v 16.2 (9.9,24.3) v 9.9 (4.5,16.2) GMFR A(H1N1) 1.4 (0.9,2.2) v 1.6 (1.0,2.6) v 1.3 (0.8,2.1) A(H3N2) 2.5 (1.7,3.7) v 2.1 (1.4,3.2) v 1.3 (0.6,1.7) B 1.0 (0.8,1.4) v 1.2 (0.8,1.7) v 1.0 (0.7,1.4)		
Scheifele (2013) ⁴¹ NCT01368796	ID: Intanza® 15µg HA/strain 0.1mL/dose	RCT Evaluator-blind Multicenter	Age ≥65 years Mean 74 years 41% male	21 day follow-up Seroconversion ID v ADV v IM15 A(H1N1) 39.0 v 49.5 v 36.3 A(H3N2) 35.3 v 44.7 v 24.7	Level I	Good
	Comparators: ADV Fluad® (Novartis) 15µg HA/strain MF59 adjuvant 0.5mL/dose	Country: Canada 8 centres) Year 2011-12	ID=301 ADV=299 IM15=305 95% Caucasian	B 15.8 v 16.6 v 10.9 Seroprotection ID v ADV v IM15 A(H1N1) 81.0 v 91.2 v 78.7 A(H3N2) 76.1 v 87.9 v 76.5 B 98.3 v 98.6 v 98.7 GMFR ID v ADV v IM15		
	IM:15 Agriflu® (Novartis)		100% vaccinated in 1 or 2 of previous	A(H1N1) 3.1 (2.9,3.5) v 4.2 (3.7,4.8)* v 2.7 (2.5,3.0) A(H3N2)		

	15µg HA/strain 0.5mL/dose Strains A/California/7/ 2009 (H1N1) A/Perth/16/200 9 (H3N2) B/Brisbane/60/ 2008		two seasons Community- dwelling or at facilities with minimal assistance	2.7 (2.5,3.1) v 3.4 (3.1,3.8)* v 2.3 (2.1,2.5) B 1.6 (1.5,1.8) v 1.6 (1.5,1.7) v 1.4 (1.3,1.5)* 180 day follow-up Seroprotection rates declined by 21.3-25.6% for A(H1N1), 17.4-26.7% for H3N2 and <3% for B strains. Notes: Data for single radial hemolysis and microneutralization assays not abstracted but were generally similar to HAI testing ID & IM15 alike re: SP;		
Sibunruang (2011) ⁴⁷	ID12: 12µg/strain (6µg/strain /site x 2 sites) ID6: 6µg HA/strain (3µg/strain/site x 2 sites) IM: (Sanofi Pasteur) 15 µg HA/strain 0.5mL/dose Strains A/California/7/ 2009 (H1N1) A/Perth/16/200 9 (H3N2) B/Brisbane/60/ 2008	RCT Open-label Country: Thailand Year: 2010	Age 60-90 years Mean 67 years Male 20% N=180 12ID=60 6ID=60 IM=60 Healthy, community dwelling	28 day follow-up Seroconversion 12ID vs 6ID vs IM A(H1N1) 45.0 v 33.3 v 43.3 A(H3N2) 25.0 v 28.3 v 35.0 B 71.7 v 75.0 v 86.7 Seroprotection 12ID vs 6ID vs IM A(H1N1) 23.3 v 25.0 v 36.0 A(H3N2) 26.7 v 23.3 v 38.3 B 76.7 v 73.3 v 76.7 GMFR 12ID vs 6ID vs IM A(H1N1) 2.4 v 2.3 v 2.7 A(H3N2) 2.0 v 2.2 v 2.4 B 5.2 v 5.4 v 7.3	Level 1	Fair-Good Small sample size Abstract (Limited data avail-able)
Camilloni (2014) ⁴⁸	ID: Intanza® (Sanofi Pasteur)	Randomized Blinding not stated	Age ≥65 years Mean 85 years Male 15%	Follow-up 1 & 6 months One month Seroprotection ID v ADV	Level II	Good Small

	15µg HA/strain 0.1mL/dose Comparator: ADV Fluad® (Novartis) 15µg/strain 0.5mL dose MF59	Country Italy Nursing homes Season 2011,2012	N=80 ID=40 ADV=40 100% previously vaccinated 100% chronic underlying disease Live in nursing home	H1N1 70.0 (57.1,80.3) v 72.5 (59.7,82.4) H3N2 92.5 (82.6,97.0) v 87.5 (76.4,93.8) B 75.0 (62.4,84.4) v 75.0 (62.4,84.4) Seroconversion ID vs ADV H1N1 42.5 (30.5,55.5) v 50.0 (37.3,62.6) H3N2 60.0 (47.0,71.7) v 47.5 (35.1,60.2) B 40.0 (28.3,53.0) v 10.0 (4.6,20.5)* GMFR ID v ADV H1N1 3.8 (2.2,6.8) v 3.7 (2.4,5.6) H3N2 4.6 (2.8,7.8) v 3.3 (1.9,5.7) B 3.2 (1.7,6.0) v 1.6 (1.3,2.0) 6 month follow-up Seroprotection ID v ADV H1N1 50.0 (37.3,62.6) v 40.0 (28.3,53.0) H3N2 67.5 (54.5,78.2) v 66.5 (52.0,76.1) B 60.0 (47.0,71.7) v 57.5 (44.5,69.5) Seroconversion ID v ADV H1N1 7.5 (3.0,17.4) v 17.5 (9.8,29.4) H3N2 17.5 (9.8,29.4) v 30.0 (19.6,42.9) B 0.0 (0,6.3) v 17.5 (9.8,29.4)* GMFR ID v ADV H1N1 1.9 (1.2,2.8) v 1.5 (1.1,2.0) H3N2 2.4 (1.3,4.4) v 2.1 (1.1,4.1) B 1.8 (1.0,3.1) v 1.0 (0.9,1.1)		sample size
Ansaldi (2013) ⁵⁰ EUDRACT: 2009–014637– 24	ID: Intanza® (Sanofi Pasteur) 15µg HA/strain 0.1ml dose Comparator: ADV Inflexal® V (Crucell) 15µg HA/strain 0.5mL/dose Adjuvant: virosome Strains	RCT Open-label Multicenter Phase IV Country: Italy Year 2010	Age: ≥60 Mean 75-77 years Total: N=50 for serology ID=24 ADV=23 Excluded: alcoholic, unstable chronic illness	Follow-up: 28 days Seroconversion ID v ADV A(H1N1) 50 (31,69) v 43 (26,43) A(H3N2) 50 (31,69) v 35 (19,55) B 46 (28,65) v 0 (0,14) Seroprotection ID v ADV A(H1N1) 63 (43,79) v 57 (37,74) A(H3N2) 71 (51,85) v 48 (29,67) B 100 (86,100) v 100 (86,100) GMFR (Cl _{95%}) ID v ADV A(H1N1) 3.4 (1.9,5.9) v 2.3 (1.3,3.8) A(H3N2) 2.9 (1.8,4.8) v 2.1 (1.4,3.1)	Level I	Fair- Good Small number for serology

49 | A REVIEW OF THE LITERATURE OF HIGH DOSE SEASONAL INFLUENZA VACCINE FOR ADULTS 65 YEARS AND OLDER

	A/California/7/ 2009(H1N1) A/Perth/16/200 9 (H3N2) B/Brisbane/60/ 2008			B 2.7 (1.5,4.9) v 1.5 (1.0,2.3) 3 month follow-up Seroprotection ID v IM A(H1N1) 45 (26,66) v 47 (27,68) A(H3N2) 60 (39,78) v 32 (15,54) B 95 (76,99) v 100 (83,100)		
Van Damme (2010) ⁴⁹ NCT00554333	ID: Intanza® (Sanofi Pasteur) 15µg HA/strain 0.1 mL/dose ADV: Fluad® (Novartis) 15µg HA/strain MF59 adjuvant 0.5mL/dose Strains A/Solomon Islands/3/2006 (H1N1) A/Wisconsin/6 7/2005 (H3N2) B/Malaysia/25 06/2004	RCT Open-label Parallel-group Multi-centre Phase II Country Belgium, France 10 centres Year 2007-08	Age ≥65 yrs Mean 74.3 yrs Male 46.5% N 795 ID=390 ADV=385 72% vaccinated last year 53% underlying disease	Follow-up: 21 days Seroprotection ID v ADV A(H1N1) 81.3 v 87.1 GMFR (Cl _{95%}) ADV/ID A(H1N1) 1.13 (0.95,1.34) ^N A(H3N2) 1.31 (1.13,1.53) B 1.08 (0.95,1.23) ^N GMTR (ADV/ID) A(H1N1) 1.12 A(H3N2) 1.31 B 1.07	Level 1	Good

Appendix F: Summary of evidence related to safety of high dose seasonal influenza vaccines in adults 65 years and older

			STUDY	DETAILS		
Study	Vaccine	Study Design	Participants	ipants Summary of Key Findings		Quality
60μg HA/stra	in inactivated in	ıtramuscular				
Couch (2007) ²⁹ NCT00115531 NCT00170508	Experimental IM: 60µg HA/strain 0.5mL/dose Comparator: Fluzone® (Sanofi Pasteur) 15µg HA/strain 0.5mL/dose Strains A/New Caledonia/20/99 (H1N1), A/Wyoming/03 /2003 (H3N2) B/Jiangsu/10/2 003	RCT Double blind Multi-site Phase II Country USA Year 2004-05 Stratified by receipt of influenza vaccine in same season	Age ≥65 Mean: 73-74 yrs Male 51% N=414 60µg=206 15µg=208 78% vaccinated in fall of 2004 (same season) 96% Caucasian	Follow up: 7 days active; 210 days passive Reactogenicity 15μg v 60μg Systemic Fever (≥37.5°C) 0.5 v 4.4 Myalgia 15.4 v 12.6 Headache 17.3 v 11.1 Malaise 13.0 v 16.5 Local Pain 19.7 v 40.3 Redness 27.9 v 29.1 Swelling 18.3 v 23.8 Vaccine-related SAE 60μg: oculo-respiratory syndrome day of vaccination	Level 1	Good
DiazGranados (2013) ²¹ NCT00976027	Fluzone® High-Dose (Sanofi Pasteur) 60µg HA/strain 0.5mL/dose Comparator: Fluzone® (Sanofi Pasteur)	RCT Double-blind Multi-centre Phase 3b Country USA 99 centres Year 2009-10	Age ≥65 yrs Mean 72.8 yrs (64–99 yrs) Male 46.3% N=9158 60µg N=6107 15µg N=3051 85% Caucasian 89% vaccinated	Follow-up 180 days, weekly calls Adverse events 60µg -3 cases of Bell's Palsy (116, 126, & 178 days post-vaccination) 15µg -2 cases of Bell's Palsy (34 & 176 days post- vaccination) Serious adverse events 15µg v 60µg At least one 197 (6.5%) v 408 (6.7%)	Level 1	Good

	15µg HA/strain 0.5mL/dose Strains A/Brisbane/59/ 07 (H1N1) A/Uruguay/716 /2007 (H3N2) B/Brisbane/60/ 2008		last season Ambulatory, medically stable Key Exclusion Criteria: Bed-ridden, Immune suppressing disease	Fatal SAE 10 (0.3%) v 24 (0.4%) Vaccine-related 2 v 1 Vaccine-related SAE 60µg -cardiac chest pain starting one day after vaccination (recovered in 2 days) 15µg -Bell's palsy 34 days after injection and unresolved at study completion -immune thrombocytopenia 13 days after injection and recovered after 5 days No reactogenicity data gathered		
DiazGranados (2014) ³³ NCT01427309	Fluzone® High- Dose (Sanofi Pasteur) 60µg HA/strain 0.5mL/dose Fluzone® 15µg HA/strain 0.5mL/dose	RCT Double-blind Multicenter Phase IIIb–IV Country USA, Canada 126 centres Yr 1 2011-12 Yr 2 2012-13	Age ≥65 yrs Mean: 73.3 yrs Male 43.4% N=31,983 60µg=15,990 15µg=15,993 95% Caucasian 74% previous vaccination 67% ≥ 1 chronic condition	Follow-up: ~180 days Vaccine-related SAE 60μg v 15μg 3 v 0 60μg: - cranial-nerve VI palsy (1 day post-vaccination) - hypovolemic shock including diarrhoea (1 day post-vaccination) - acute disseminated encephalomyelitis (117 days post-vaccination)	Level 1	Good
Falsey (2009) ²⁸ NCT00391053	Experimental TIV split-virus 60µg/strain 0.5mL/dose Comparator: Fluzone® (Sanofi Pasteur) 15µg HA/strain	RCT Double-blind Multi-centre Phase III Country USA 30 centres Year 2006-07	Age 65-97 years Mean 73 years Male 52% N=3876 60µg=2576 15µg=1275 82% vaccinated last season	Follow-up 7 days active, 180 days passive Reactogenicity 60μg v 15μg Systemic Fever (≥ 37.5 °C) 3.6 (2.9,4.4) v 2.3 (1.5,3.3) 1.1 (0.8,1.6) v 0.3 (0.1,0.8)* mod/severe Myalgia 21.4 (19.8,23.0) v 18.3 (16.2,20.5) 5.8 (5.0,6.8) v 3.4 (2.5,4.6)* mod/severe	Level 1	Good.

Sanofi Pasteur	0.5mL /dose Strains A/New Caledonia/20/99 (H1N1) A/Wisconsin/67/ 2005 (H3N2) B/Malaysia/2506 /04 Fluzone®	RCT	79% underlying condition Medically stable, community dwelling Age ≥ 65 yrs	hospitalization (2 da 15µg: Myasthenia gi vaccination)	4.0 (12.1,16.0)* tion 9.4 (26.9,32.0)* LE se exacerbation requiring	Level 1	Good
Robertson	High-Dose (Sanofi	Double-blind Multi-centre	Mean: 72.1 yrs Male: 39%	Reactogenicity	60μg v 15μg		
	Pasteur) 60µg HA/strain	Phase IV	N=300	Systemic Fever (undefined)	0.7 v 1.3		
	0.5mL/dose	Country	60µg=145	Myalgia	29.3 v 16.7*		
	Comparator:	USA 6 centres	15µg=147	Headache Malaise	16.7 v 17.3 16.0 v 14.0		
	Fluzone®	V 0044 40	96% Caucasian	Local	50.7 04.0*		
	(Sanofi Pasteur)	Year 2011-12		Pain Erythema	52.7 v 24.0* 8.7 v 4.7		
	15µg HÁ/strain			Swelling	6.7 v 2.7		
'	0.5mL/dose			Vaccine-related SA	Æ		
	Strains			None			
	A/California/07 /2009 (H1N1)						
	A/Victoria/210/ 2009 (H3N2)						
	B/Brisbane/60/						
	2008						

Talbot (2014) ⁵⁹	Fluzone® High-Dose	RCT Double-blind	Age 67-79 yrs Mean 73 yrs	Follow-up Not specified	Level 1	Fair
NCT01189123	(Sanofi Pasteur) 60µg HA/strain 0.5mL/dose Comparator: Fluzone® (Sanofi Pasteur) 15µg HA/strain 0.5mL/dose	Single centre Country USA Years: not stated (possibly 2010-2012)	Male 51.4% N=105 60µg=47 15µg=50	Vaccine-related SAE No SAE		Small sample size
	Strains not stated					
Tsang (2014) ³²	60IM: High	RCT	Age 47-99 years	Follow-up 7 days active; 180 days passive	Level I	Good
NCT00551031	Dose IM15 (Sanofi	Open label for route	Mean 73 years Male 44%	Bootogonioity		
NC100551031	Pasteur)	Double-blind for	Male 44%	Reactogenicity Local		
	60µg/strain	dose Multi-	N=1912	15ID v 21 ID 76.5 (73.0, 79.8) v 77.3 (73.8,		
	0.5mL IM	centre Phase II	60IM=319	80.5)		
			15IM=320	60 v 15IM 34.5 (29.3, 40.0) v 49.5 (43.9,		
	Investigational	Country USA	15ID=635	55.2)*		
	ID (Sanofi	31 centres	21ID=635	Systemic		
	Pasteur) 15ID:	Year 2007-08	070/ mmaxia.cal./	15ID v 21ID 27.2 (23.8, 30.9) v 31.1 (27.5,		
	15µg/strain	Year 2007-08	87% previously vaccinated	34.9) 15IM v 60IM 25.7 (21.0, 30.9) v 36.4 (31.1,		
	0.1 mL/dose		94% Caucasian	41.9)*		
	ID			Immediate unsolicited events		
	21ID:		Medically stable	15ID: Moderate dizziness lasting one day		
	21µg/strain		Ambulatory	15IM: Moderate jaw pain lasting one day		
	0.1 mL/dose			Vassina valete dama eliaite d AF		
	Comporator			Vaccine-related unsolicited AE 15ID v 21ID 2.7 (1.6, 4.3) v 2.4 (1.3, 3.9)		
	Comparator: FluZone®			15IM v 60IM 1.6 (0.5, 3.6) v 1.6 (0.5, 3.6)		
	(Sanofi			1.0 (0.0, 0.0) v 1.0 (0.0, 0.0)		
	Pasteur)			Severe vaccine-related non-serious AE		
	15IM:			21ID: severe injection-site rash		
	15µg/strain			60IM: Severe vomiting (on vaccination day)		

. •	0.5mL/dose Strains A/Solomon Islands/3/2006 (H1N1) A/Wisconsin/6 7/2005 (H3N2) B/Malaysia/25 06/2004 ed, intramuscular			SAE 15ID v 21ID 5.4 (3.7,7.4) v 6.0 (4.3,8.1) 15IM v 60IM 6.6 (4.1,9.9) v 5.0 (2.9,8.0) Vaccine related SAE None reported		
Keitel (2006) ³⁰	Subvirion TIV (Aventis Pasteur) 30µg HA/strain 60µg HA/strain 0.5mL/dose Comparator: subvirion TIV (Aventis Pasteur) 15µg HA/strain 0.5mL/dose Placebo: saline Strains A/NewCaledonia /20/99 (H1N1) A/Panama/2007/ 99 (H3N2) B/Victoria/504/2 000	RCT Single-center Country USA Year 2001-02	Age ≥65 years Mean 72.4 yrs (65-88 yrs) Male 59 % N=202 60µg=50 30µg=51 15µg=51 Saline=50 97% Caucasian 82% vaccinated last season Ambulatory, medically stable .	Follow-up 7 days; 180 passive Local Reaction 60 v 30 v 15μg v saline Any 12 v 24 v 20 v 22 (not significant) Redness/swelling 6% of high dose Significant dose-related increases in discomfort and redness/swelling (p<0.005) Systemic Reaction (%) No significant differences among groups SAE 3 in each of the vaccine groups Vaccine-related SAE None	Level 1	Good
Palache	cular - subunit Experimental	RCT	Data for 65+ yrs	Follow-up 2 days of active	Level I	Good
(1993) ³⁹	trivalent subunit (Duphar BV) 60 µg	Double-blind Multi-centre Placebo- controlled	Age 68-99 yrs Mean 80 yrs	Reactogenicity Placebo v 10 v 20 v 60µg Systemic Any 1 v 0 v 2 v 0	LGVGI I	3000

	HA/strain 0.5mL/dose Comparator(s) 10µg HA/strain 20 µg HA/strain Saline (placebo) 0.5mL/dose Strains A/Taiwan/2/86 (H1N1) A/Sichuan/2/8 7 (H3N2) B/Beijing/1/87	Country Netherlands Israel Year 1988 See Remarque (1993) for same participants – for IgG, IgA, IgM responses to H3N2 strain	60 µg=66 10 µg=67 20 µg=64 Saline=65 22% previously vaccinated Nursing home residents Excluded Immune suppressing drug treatment	Local Any 3 v 1 v 5 v 6 SAE none reported		
Recombinant	vaccines					
Keitel (2009) ²³ NCT00395174	FluBlok® (Protein Sciences Corp.) ~45µg rHA/strain 0.5mL/dose (Total: 131µg) Strains A/Wisconsin (H3N2) A/New Caledonia (H1N1) B/Ohio IM15: Fluzone® (Sanofi Pasteur)	RCT Double-blind Multi-centre Phase 3 Country USA 7 centres Year 2006-07	Age ≥65 yrs Mean: 45µg 72.9 yrs 15µg 73.9 yrs Male 47% N=869 rHA45=431 IM15=430 98% Caucasian 83% vaccinated last season Ambulatory, medically- stable, community dwelling	Follow-up: 7 days active, 180 days passive Reactogenicity rHA45 v IM15 Any 47 v 50% Systemic Fever (≥37.6°C) 2.5 v 2.1 Headache 11 v 10 Tiredness 14 v 15 Fatigue 9 v 10 Local Discomfort 22 v 23 Erythema 10 v 12 Swelling 7 v 10 Erythema immediately after injection 6.1 v 0.6* Unsolicited AE 21% v 20% Vaccine-related SAE None	Level 1	Good

	15µg HA/strain 0.5mL/dose						
Treanor (2006) ⁴⁰	Baculovirus- expressed (rHA) 135µg rHA/strain 45µg rHA/strain 15µg rHA/strain 0.5mL/dose Comparator IM15: Fluzone® (Sanofi Pasteur). 15µg HA/strain 0.5mL/dose Strains A/Panama/2007/ 99 (H3N2) A/NewCaledonia /20/99 (H1N1) B/HongKong/33 0/2001	RCT Double-blind Country USA Year not stated (2002-03 or 2003-04)	Age 65-90 yrs Mean: 72 yrs 49% male N=399 135rHA=101 45rHA=98 IM=98 96% Caucasian Community-dwelling, medically stable	Systemic Fever (≥37.5°C) 4.0 v 4.0 Myalgia 15.0 v 8.0 Headache 15.0 v 14. Malaise 15.0 v 14. Local 19.0 v 15. Swelling 11.0 v 0 v	v 3.0 v 2.0 v 11.1 v 8.1 0 v 15.2 v 10.1 0 v 13.1 v 7.1	Level 1	Good
	ted intradermal						T
Ansaldi (2013) ⁵⁰ EUDRACT: 2009–014637– 24	ID: Intanza® (Sanofi Pasteur) 15µg HA/strain 0.1ml dose Comparator: Inflexal® V (Crucell) 15µg HA/strain 0.5mL/dose	RCT Open-label Multicenter Phase IV Country: Italy Year 2010	Age: ≥60 Mean 75-77 years Total: N=500 ID: n=250 IM: n=250 Excluded: alcoholic, unstable chronic	Follow-up 21 days active; 18 Reactogenicity IM v ID Systemic 10 (7,15) v 2 Any 10 (7,15) v 2 Fever (≥38°C): 2 (1,14) v 2 Chills/shivering: 5 (3,9) v 3 (2 Myalgia: 7 (4,11) v 6 Headache: 6 (3,10) v 4 Malaise: 6 (3,10) v 5 Local	11 (7,15) (1,14) 2,6) (4,10) (2,8)	Level I	Good

	Strains A/California/7/ 2009(H1N1) A/Perth/16/200 9 (H3N2) B/Brisbane/60/ 2008		illness	Any: 20 (15,26) v 43 (36,49) Pain: 12 (8,17) v 13 (9,18) Redness: 7 (4,11)* v 33 (27,39) Swelling: 5 (2, 8)* v 19 (14,24) Lump: 7 (4,11)* v 25 (20,31) Pruritus: 5 (3,9)* v 20 (16,26) Unsolicited Events, days 0-21		
Arnou (2009) ⁴⁶ NCT00383526	Experimental ID: (Sanofi Pasteur) 15ug HA/strain 0.1mL/dose Comparator: Vaxigrip® (Sanofi Pasteur) 15ug HA/strain 0.5mL/dose Strains as recommended for 2006-2007 2007-2008 2008-2009 *Analysis includes only participants vaccinated with the same vaccine sequentially	RCT Open-label Multi-centre Country: France, Belgium, Lithuania, Italy Years 2006-2009	Age 60-95 years Mean 71 years Male 20% N=3707 Year 1 ID =2604 IM =1081 Year 2 ID→ID =133 IM→IM =143 Year 3 ID→ID→ID=121 IM→IM→IM=67 65% chronic condition Excluded congenital or acquired immunodeficiency	Follow up 7 days active; 21 days passive Reactogenicity IM v ID Systemic Fever (>37.5°C & ≥24 hr) 3.4 (2.4,4.7) v 2.5 (1.9,3.1) Chills 6.1 (4.7,7.7) v 4.6 (3.8,5.5) Myalgia 10.9 (9.1,12.9) v 10.6 (9.5,11.9) Headache 12.7 (10.8,14.9) v 13.0 (11.8,14.4) Malaise 7.8 (6.3,9.6) v 8.5 (7.4,9.6) Local Pain 17.2 (15.0,19.6) v 22.7 (21.1,24.4) Redness 15.1 (13.0,17.3)* v 70.9 (69.1,72.7) Swelling 8.4 (6.8,10.2)* v 35.8 (33.9,37.7) Lump 11.3 (9.5,13.3)* v 37.6 (35.8,39.5) Pruritus 6.1 (4.7,7.7)* v 29.5 (27.7,31.2) Bruising 3.7 (2.7,5.0) v 3.4 (2.7,4.2) Unsolicited reactions (Day 0-21) 1.8 (1.1,2.8) v 1.6 (1.2,2.2) SAE IM v ID 0.6 (0.2,1.2) v 0.5 (0.3,0.9) SAE possibly vaccine-related IM=0 v ID=2 -myopericarditis 4 months post-vaccination in a person with history of MI	Level 1	Good

Chan (2014) ⁴⁴	Intanza® (Sanofi	RCT Open-label	Age ≥65 years Mean 83 years	Follow-up: 7 days active; 180 days passive Reactogenicity IM v ID	Level I	Good
NCT01967368	Pasteur) 15µg HA/strain 0.1mL/dose Comparator: Vaxigrip® (Sanofi Pasteur) 15µg HA/strain 0.5mL/dose Strains A/California/7/ 2009 (H1N1), A/Victoria/361/ 2011 (H3N2) B/Massachusetts/2/2012	Single center Country: China (Hong Kong) Year 2013-14	Male 36% Total: n=100 ID=50 IM=50 Nursing home residents	SystemicFever (≥37.5°C)4 v 2Myalgia6 v 10Arthralgia4 v 8Headache6 v 6Malaise8 v 12LocalPain6 v 4Redness4 v 26*Swelling2 v 20*Lump0 v 0 Serious adverse events: No vaccine-related SAE		
Hoon Han (2013) ⁴³ NCT01215669	Intanza® (IDflu) 15µg HA/strain 0.1mL/dose Comparator: Vaxigrip® (Sanofi Pasteur) 15µg HA/strain 0.5 mL/dose Strains A/California/7/ 2009 (H1N1) A/Perth/16/200 9 (H3N2) B/Brisbane/60/ 2008	RCT Open-label Multicentre Phase IV Country South Korea 6 sites Year 2010-11	Age: 18+ years Data for ≥60 years Mean 64.5-64.9 yrs Male 38% N: 120 ID: n= 60 IM: n= 60 38% vaccinated past year	Follow-up: 7 days active, 21 days passive Reactogenicity IM v ID Systemic Fever (>38.0°C & ≥1 day) 0 v 0 Shivering 13.3 v 18.3 Malaise 13.3 v 20.0 Local Induration (≥50mm & ≥3 days) 0 v 0 Pain, erythema, swelling, induration, and pruritus were higher in ID than IM recipients Unsolicited AE IM v ID Any 25 V 23.3 Vaccine-related 3.3 v 3.3 SAE None	Level I	Good

Holland (2008) ⁴² NCT00296829	Intradermal split-virion (Sanofi Pasteur) 15µg HA/strain 21µg HA/ strain 0.1mL/dose Comparator: VaxiGrip® (Sanofi Pasteur) 15µg HA/strain 0.5mL/dose Strains A/New Caledonia/20/99 (H1N1) A/Wellington/1/2004 (H3N2) B/Jiangsu/10/2003	RCT Open label for route Double blind for dose Multicenter Phase II Country New Zealand Australia Year 2006	Age 65-85 yrs Males 47% Total n=1101 15ID=366 21ID=369 15IM=366 ~85% vaccinated previous season Medically stable	Follow-up 7 days reactogenicity; 180 days SAE Reactogenicity 15IM v 15ID v 21ID Systemic Any 27.4 v 30.2 v 29.1 Fever (>37.5°C & >24hr) 4.1 v 3.9 v 4.1 Chills 0.8 v 0.5 v 2.2 Myalgia 12.2 v 12.4 v 12.2 Headache 17.4 v 18.1 v 16.0 Malaise 10.1 v 13.2 v 10.1 Local Any Any 39.7* v 89.6 v 88.0 Pain 16.8 v 18.4 v 16.3 Erythema 19.1* v 78.8 v 77.7 Swelling 13.4* v 62.3 v 58.2 Pruritus 8.7* v 27.2 v 32.1 Induration 16.7* v 64.6 v 65.2 Vaccine-related SAE (180 days) 15ID - 1 vaccine-related, brachial neuritis	Level 1	Good
Seo (2014) ⁴⁵	ID: (Sanofi Pasteur) 15µg HA/strain 0.1mL/dose IM15: Aggripal S1® (Novartis) 15µg HA/strain 0.1mL/dose ADV: Fluad® (Novartis) 15µg HA/strain 0.1mL/dose adjuvant	RCT Multicenter Country South Korea	Age ≥65 years Median 71-73 years Male 32-39% N=335 IM =113 ADV=111 ID =111 Community- dwelling Good health	Follow-up: 7 day active Reactogenicity IM v ID v ADV Systemic 0 v 0.9 v 0 Fever (≥38°C) 0 v 0.9 v 0 Chills/shivering 1.2 v 0 v 2.7 Myalgia 0.9 v 5.4 v 8.1 Arthralgia 0.9 v 2.7 v 5.4 Headache 0.9 v 4.5 v 2.7 Fatigue 0.9 v 5.4 v 5.4 Malaise 0 v 4.5 v 5.4 Local Pain Pain 7.1 v 6.3 v 10.8 Redness 3.5 v 9.9 v 5.4 Swelling 3.5 v 6.3 v 2.7	Level I	Fair Short follow-up of SAE

	Year 2011-12 Strains A/California/7/ 2009 (H1N1) A/Perth/16/200 9 (H3N2) B/Brisbane/60/ 2008			SAE None reported		
Scheifele (2013) ⁴¹ NCT01368796	ID: Intanza® (Sanofi Pasteur) 15µg HA/strain 0.1mL/dose Comparators ADV: Fluad® (Novartis) 15µg HA/strain MF59 adjuvant 0.5mL/dose IM15: Agriflu® (Novartis) 15µg HA/strain 0.5mL/dose Strains A/California/7/ 2009 (H1N1) A/Perth/16/200 9 (H3N2) B/Brisbane/60/ 2008	RCT Evaluator-blind Multicenter Country: Canada 8 centres) Year 2011-12	Age ≥65 years Mean 74 years 41% male ID=301 ADV=299 IM=305 95% Caucasian 100% vaccinated in 1 or 2 of previous two seasons Community- dwelling or at facilities with minimal assistance	Reactogenicity IM v ID v ADV Systemic Any 39.4 (34.1,45.0) v 43.6 (38.1,49.2)* v 39.9 (34.5,45.5) Fever 0.7-1.7% across groups Myalgia 18.9 (14.9,23.6) v 22.8 (18.4,27.8)* v 25.9 (21.3,31.1)* Headache 11.4 (8.3,15.4) v 14.5 (11.0,18.9) v 9.6 (6.8,13.5) Malaise 11.4 (8.3,15.4)* v 16.2 (12.5,20.7)* v 11.0 (7.9,15.0)* Tiredness 21.2 (17.0, 26.1)* v 23.8(19.3,28.9)* v 18.6 (14.6,23.4)* Arthralgia 11.1 (8.0, 15.1) v 14.2 (10.7,18.6) v 12.6 (9.3,16.9) Sleep disturbance 7.2 (4.8,10.6) v 7.9 (5.4,11.5) v 8.3 (5.7,12.0) Local Pain 20.8 v 29.7 v 37.9 Redness 12.7 v 76.2* v 13.0 Swelling 6.2 v 49.2* v 12.0 Lump 4.6 v 46.5* v 8.0 Itchiness 1.6 v 20.8* v 3.0 SAE Day 0-20 8 Day 21-180 37	Level 1	Good
				Vaccine-related SAE None		

Van Damme (2010) ⁴⁹ NCT00554333	ID: Intanza® (Sanofi Pasteur) 15µg HA/strain 0.1 mL/dose Comparator ADV: Fluad® (Novartis) 15µg HA/strain MF59 adjuvant 0.5mL/dose Strains A/Solomon Islands/3/2006 (H1N1) A/Wisconsin/6 7/2005 (H3N2) B/Malaysia/25 06/2004	RCT Open-label Parallel-group Multi-centre Phase II Country Belgium, France 10 centres Year 2007-08	Age ≥65 yrs Mean 74.3 yrs Male 46.5% N 795 ID=390 ADV=385 72% vaccinated last year 53% underlying disease	Follow up 7 days active, 21 days passive Reactogenicity ID v ADV Systemic Fever (≥38°C) 4.0 v 5.8 Chills/shivering* 6.0 (3.9, 8.8) v 5.8 (3.7, 8.6) Malaise 4.8 (2.9, 7.4) v 5.0 (3.1 v 7.7) Local Pain 19.8 v 20.9 Redness 63.1 v 13.4* Swelling 34.2 v 8.6* Lump (induration) 32.9 v 10.6* Pruritis 28.1 v 6.5* At least one 70.1 v 33.8* No immediate AE Unsolicited AE Total 26.4 v 25.9 Severe 2.0 v 1.8 Vaccine-related SAE ID: Pneumonia (one day post vaccination) ADV: Facial herpes zoster (three days post vaccination)	Level I	Good
Della Cioppa (2012) ³⁶ Della Cioppa (2014) ³⁷ NCT00848848	IM30: 30µg H3N2 with 15µg each of H1N1 & B strains (no adjuvant) 0.5mL/dose ADV30: 30µg H3N2 with 15µg each of H1N1 & B strains & MF59 (100%) 0.5mL/dose IM15: 15µg /strain (no	RCT Observer-blind Multicenter Countries Poland Belgium Germany Year 2008-09	Age ≥65 yrs Mean 69 yrs Male 40-68% N=450 IM30=43 ADV30=42 IM15=43 ADV15=46 ID12=46 (other groups excluded) 73-81% previously vaccinated	Follow-up 7 days active, 21 days passive Systemic:IM30 v ADV30 v IM15 v ADV15 v ID12 Fever (≥38.0°C) 0 v 0 v 0 v 0 v NR Chills 0 v 2 v 0 v 2 v NR Myalgia 2 v 2 v 0 v 2 v 6 Headache 2 v 0 v 0 v 0 v NR Malaise 0 v 2 v 0 v 0 v NR Arthralgia 0 v 2 v 0 v 2 v NR Local Pain ADV significantly higher than IM or ID Erythema 0 v 2 v 0 v 0 v 47-52 Swelling ID significantly higher Induration ID significantly higher Pruritus Not stated for IM; ID12-2-6%	Level 1	Good

62 | A REVIEW OF THE LITERATURE OF HIGH DOSE SEASONAL INFLUENZA VACCINE FOR ADULTS 65 YEARS AND OLDER

adjuvant)		la althu	Vaccine-related SAE	
0.5mL/dose		Healthy volunteers	None	
ADV15:15µg				
/strain & MF59)		NB	
(100%) Fluad ®			NR: not reported	
(Novartis)				
0.5mL/dose				
Strains	,			
A/Brisbane/59	/			
2007 (H1N1)				
A/Uruguay/71				
/2007 (H3N2)				
B/Florida/4/20				
06				

ADV: adjuvant; ID: intradermal; IM: intramuscular; AE: adverse event; SAE: serious adverse event